COMPOSES DE 1H-QUINOLIN-4-ONE, PROCEDES, UTILISATIONS ET COMPOSITIONS

1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS

Abrégé français

La présente invention concerne de nouveaux composés de 1H-quinolin-4-one répondant à la formule (I), R1, R2, R3, R4 et R5 ayant différentes significations, et leurs sels et hydrates pharmaceutiquement acceptables. Les composés répondant à la formule (I) se révèlent utiles pour traiter ou prévenir des maladies associées à la modulation des récepteurs GABAA, l'anxiété, l'épilepsie, les troubles du sommeil, notamment l'insomnie, et pour induire une hypnose associée à une sédation, une anesthésie, le sommeil et une relaxation musculaire. L'invention concerne également des procédés de synthèse servant à préparer lesdits composés.

Abrégé anglais

The invention provides new 1H-quinolin-4-one compounds of formula (I), wherein R1, R2, R3, R4 and R 5 have different meanings, and pharmaceutically acceptable salts and hydrates thereof. Compounds of formula (I) are useful for treating or preventing diseases associated with GABAA receptors modulation, anxiety, epilepsy, sleep disorders including insomnia, and for inducing sedation-hypnosis, anesthesia, sleep and muscle relaxation. The invention also provides synthetic procedures for preparing said compounds.

Revendications

42
CLAIMS
1. A 1H-quinolin-one compound of formula (1):
<IMG>
wherein
R1 and R2 are independently selected from the group consisting of
hydrogen, alkyl(C1-C6), Oalkyl(C1-C6), halogen and phenyl;
R3 and R4 are independently selected from the group consisting of
hydrogen and phenyl optionally substituted by alkyl(C1-C6), halogen and
Oalkyl(C1-C6);
R5 is selected from the group consisting of R5 is selected from the group
consisting of NR6R7, N(R8)NH2 and a heteroaryl ring selected from the
group consisting of pyridyl, furyl, thienyl, oxazolyl, isoxazolyl, imidazolyl,
pyrrolyl, pyrazolyl, pyrimidinyl and pyrazinyl, wherein each heteroaryl ring
contains one or two optional alkyl(C1-C6) substituents;
R6 and R7 are independently selected from the group consisting of
hydrogen; alkyl(C1-C6); alkenyl(C2-C6); cycloalkyl(C3-C6)alkyl(C1-C6);
hydroxyalkyl(C1-C6); heteroaryl selected from the group consisting of
pyridyl, pyrimidinyl, pyrazinyl, thiazolyl, benzothiazolyl, oxazolyl,
benzoxazolyl, isoxazolyl, benzisoxazolyl, pyrazolyl, furyl, benzofuryl,
thienyl, benzothienyl, thiadiazolyl, pyrrolyl, imidazolyl, benzimidazolyl,
indolyl, quinolyl and isoquinolyl, wherein each heteroaryl contains one or

43
two optional substituents independently selected from the group consisting
of alkyl(C1-C6), Oalkyl(C1-C6), haloalkyl(C1-C6), cycloalkyl(C3-C6), NO2 and
COalkyl(C1-C6); thienylalkyl(C1-C6), furylalkyl(C1-C6), pyridylalkyl(C1-C6);
and aryl selected from the group consisting of phenyl and indanyl, wherein
each aryl contains one or two optional substituents selected from the group
consisting of alkyl(C1-C6), haloalkyl(C1-C6), halogen, Ndialkyl(C1-C6),
NHalkyl(C1-C6), Oalkyl(C1-C6), NO2, CN, OH, NH2, COOH, COalkyl(C1-C6),
COOalkyl(C1-C6), CONHalkyl(C1-C6), CONdialkyl(C1-C6) and COphenyl;
with the proviso that NR6R7 is not NH2, NH(C1-C4 alkyl) or N(C1-C4 alkyl)2;
or R6 and R7 can form, together with the nitrogen atom to which they are
attached, a heterocycle selected from pyrrolidine, 3-pyrroline, 1,2,3,6-
tetrahydropyridine, piperidine, morpholine, thiomorpholine and piperazine,
wherein each heterocycle contains one, two, three or four optional
substituents selected from the group consisting of OH, alkyl(C1-C6) and
COalkyl(C1-C6);
R8 is selected from the group consisting of hydrogen and alkyl(C1-C6); and
R9 is alkyl(C1-C6);
with the proviso that R3 and R4 cannot be hydrogen simultaneously;
and pharmaceutically acceptable salts and hydrates thereof.
2. The compound of claim 1 wherein R1 is selected from the group
consisting of hydrogen, alkyl(C1-C6), Oalkyl(C1-C6), halogen and phenyl;
R2 is selected from the group consisting of hydrogen, alkyl(C1-C6), halogen
and phenyl; and R3, R4, R5, R6 ,R7, R8 and R9 are as defined in claim 1.
3. A compound according to any one of the preceding claims, wherein
R1 and R2 are independently selected from the group consisting of
hydrogen, methyl, bromine and phenyl.

44
4. A compound according to any one of the preceding claims, wherein
R3 and R4 are independently selected from the group consisting of
hydrogen, phenyl, 4-fluorophenyl, 4-chlorophenyl, p-tolyl and 4-
methoxyphenyl.
A compound according to one of the preceding claims, wherein R5 is
selected from the group consisting of NHNH2, N(methyl)NH2, 2-pyridyl, 3-
pyridyl, 4-pyridyl, 2-pyrazinyl, 5-methyl-2-furyl, 2-thienyl and 2,4-dimethyl-
5-
oxazolyl
6. A compound according to one of the preceding claims, wherein R6
and R7 are independently selected from the group consisting of hexyl, allyl,
hydroxyethyl, cyclopropylmethyl, 1,3,4-thiadiazol-2-yl; 1,3-dimethyl-5-
pyrazolyl, 1-methyl-3-pyrazolyl, 2,5-dimethyl-3-pyrrolinyl, 1,2,3,6-
tetrahydropiperidinyl, 2,5-dimethyl-3-pyrazolyl, 2-acetyl-3-thienyl, 2-
indanyl,
2-methyl-3-pyrazolyl, 2-methyl-5-indolyl, 2-pyrazinyl, 2-pyrimidinyl, 2-
quinolyl, 2-thiazolyl, 3,5-isoxazol-4-yl, 3-isoxazolyl, 3-methyl-2-
thienylmethyl, 3-methyl-5-isoxazolyl, 3-methyl-6-pyridyl, 3-methylisoxazol-5-
yl, 3-oxazolyl, 3-pyrazolyl, 1,3,4-thiadiazol-2-yl, 4-methyl-2-thiazolyl, 5-
trifluoromethyl-1,3,4-thiadiazol-2-yl, 5-cyclopropyl-3-pyrazolyl, 5-methyl-2-
pyridyl, 5-methyl-3-pyrazolyl, 5-methyl-isoxazol-3-yl, 5-nitro-2-thiazol-2-yl,
6-methoxy-4-pyrimidinyl, 2-furylmethyl, 2-pyridylmethyl, 2-thienylethyl,
phenyl, p-tolyl, 4-trifluoromethylphenyl, 4-dimethylaminophenyl, 4-
fluorophenyl and 4-methoxyphenyl, or R6 and R7 form, together with the
nitrogen atom to which they are attached, pyrrole, 2,5-dimethyl-3-pyrroline,
piperidine, 1,2,3,6-tetrahydropyridine, 4-hydroxypiperidine, 3,5-
dimethylpiperidine, morpholine, 2,6-dimethylmorpholine, 4-methylpiperazine
and 4-acetylpiperazine.
7 A compound selected from the group consisting of
5-Methyl-1-(2-morpholin-4-yl-2-oxo-ethyl)-2-phenyl-1H-quinolin-4-one;
N, N-Diethyl-2-(7-methyl-4-oxo-2-phenyl-4H-quinolin-1-yl)-acetamide;
7-Methyl-1-(2-morpholin-4-yl-2-oxo-ethyl)-2-phenyl-1H-quinolin-4-one;

45
(7-Methyl-4-oxo-2-phenyl-4H-quinolin-1-yl)-acetic acid ethyl ester;
N,N-Dibutyl-2-(7-methyl-4-oxo-2-phenyl-4H-quinolin-1-yl)-acetamide;
N,N-Diisopropyl-2-(5-methyl-4-oxo-2-phenyl-4H-quinolin-1-yl)-acetamide;
5-Methyl-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-2-phenyl-1H-quinolin-4-one;
2-(7-Methyl-4-oxo-2-phenyl-4H-quinolin-1-yl)-N,N-dipropyl-acetamide;
N,N-Dihexyl-2-(5-methyl-4-oxo-2-phenyl-4H-quinolin-1-yl)-acetamide;
5-Methyl-1-(2-oxo-2-piperidin-1-yl-ethyl)-2-phenyl-1H-quinolin-4-one;
5-Methyl-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-2-phenyl-1H-quinolin-4-one;
7-Methyl-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-2-phenyl-1H-quinolin-4-one;
N,N-Dibutyl-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N,N-dipropyl-acetamide;
7-Methyl-1-(2-oxo-2-piperidin-1-yl-ethyl)-3-phenyl-1H-quinolin-4-one;
N,N-Dihexyl-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetamide;
N,N-Diethyl-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetamide;
7-Methyl-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-3-phenyl-1H-quinolin-4-one;
7-Methyl-1-(2-morpholin-4-yl-2-oxo-ethyl)-3-phenyl-1H-quinolin-4-one;
N,N-Diisopropyl-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetamide;
N,N-Dihexyl-2-(5-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetamide;
5-Methyl-1-(2-oxo-2-piperidin-1-yl-ethyl)-3-phenyl-1H-quinolin-4-one;
5-Methyl-1-(2-morpholin-4-y1-2-oxo-ethyl)-3-phenyl-1H-quinolin-4-one;
N,N-Diethyl-2-(5-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetamide;
N,N-Dibutyl-2-(5-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetamide;
7-Methyl-1-(2-oxo-2-pyridin-3-yl-ethyl)-3-phenyl-1H-quinolin-4-one;
7-Methyl-1-(2-oxo-2-thiophen-2-yl-ethyl)-3-phenyl-1H-quinolin-4-one;
7-Methyl-1-(2-oxo-2-pyridin-2-yl-ethyl)-3-phenyl-1H-quinolin-4-one;
7-Methyl-1-(2-oxo-2-pyridin-4-yl-ethyl)-3-phenyl-1H-quinolin-4-one;
1-[2-(4-Acetyl-piperazin-1-yl)-2-oxo-ethyl]-7-methyl-3-phenyl-1H-quinolin-4-
one;
7-Methyl-1-[2-(5-methyl-furan-2-yl)-2-oxo-ethyl]-3-phenyl-1H-quinolin-4-
one;
1-[2-(2,6-Dimethyl-morpholin-4-yl)-2-oxo-ethyl]-7-methyl-3-phenyl-1H-
quinolin-4-one;
1-[2-(2,4-Dimethyl-oxazol-5-yl)-2-oxo-ethyl]-7-methyl-3-phenyl-1H-quinolin-
4-one;

46
7-Methyl-1-(2-oxo-2-pyrazin-2-yl-ethyl)-3-phenyl-1H-quinolin-4-one;
7-Methyl-1-[2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-3-phenyl-1H-quinolin-4-
one;
2-[3-(4-Methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N,N-dipropyl-
acetamide;
2-[3-(4-Chloro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N,N-dipropyl-
acetamide;
2-(7-Methyl-4-oxo-3-p-tolyl-4H-quinolin-1-yl)-N,N-dipropyl-acetamide;
N-Cyclopropylmethyl-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-
propyl-acetamide;
1-[2-(3,5-Dimethyl-piperidin-1-yl)-2-oxo-ethyl]-7-methyl-3-phenyl-1H-
quinolin-4-one;
1-[2-(3,6-Dihydro-2H-pyridin-1-yl)-2-oxo-ethyl]-7-methyl-3-phenyl-1H-
quinolin-4-one;
1-[2-(2,5-Dimethyl-2,5-dihydro-pyrrol-1-yl)-2-oxo-ethyl]-7-methyl-3-phenyl-
1H-quinolin-4-one;
N,N-Diallyl-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetamide;
2-(7-Bromo-4-oxo-3-phenyl-4H-quinolin-1-yl)-N,N-dipropyl-acetamide;
2-(5-Bromo-4-oxo-3-phenyl-4H-quinolin-1-yl)-N,N-dipropyl-acetamide;
2-(4-Oxo-3,7-diphenyl-4H-quinolin-1-yl)-N,N-dipropyl-acetamide;
2-(4-Oxo-3-phenyl-4H-quinolin-1-yl)-N,N-dipropyl-acetamide;
2-(4-Oxo-3,5-diphenyl-4H-quinolin-1-yl)-N,N-dipropyl-acetamide;
(7-Methyl-4-oxo-3-p-tolyl-4H-quinolin-1-yl)-acetic acid methyl ester;
(7-Methyl-4-oxo-3-p-tolyl-4H-quinolin-1-yl)-acetic acid;
[3-(4-Chloro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-acetic acid methyl
ester;
[3-(4-Fluoro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-acetic acid methyl
ester;
[3-(4-Fluoro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-acetic acid;
2-[3-(4-Chloro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N-phenyl-
acetamide;
2-[3-(4-Chloro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N-pyrazin-2-yl-
acetamide;
[3-(4-Chloro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-acetic acid;

47
[3-(4-Chloro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-acetic acid hydrazide;
2-(7-Methyl-4-oxo-3-p-tolyl-4H-quinolin-1-yl)-N-phenyl-acetamide;
2-[3-(4-Fluoro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N-phenyl-
acetamide;
2-(7-Methyl-4-oxo-3-p-tolyl-4H-quinolin-1-yl)-N-thiazol-2-yl-acetamide;
N-(5-Methyl-isoxazol-3-yl)-2-(7-methyl-4-oxo-3-p-tolyl-4H-quinolin-1-yl)-
acetamide;
[3-(4-Fluoro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-acetic acid hydrazide;
(7-Methyl-4-oxo-3-p-tolyl-4H-quinolin-1-yl)-acetic acid hydrazide;
2-[3-(4-Chloro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N-(5-methyl-
isoxazol-3-yl)-acetamide;
2-[3-(4-Fluoro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N-(5-methyl-
isoxazol-3-yl)-acetamide;
N-Ethyl-N-(2-hydroxy-ethyl)-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-
acetamide;
N-(2-Hydroxy-ethyl)-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-propyl-
acetamide;
N,N-Diallyl-2-(5-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetamide;
N-(2-Hydroxy-ethyl)-2-(5-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-propyl-
acetamide;
(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetic acid;
(5-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetic acid;
[3-(4-Chloro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-acetic acid N-methyl-
hydrazide;
(7-Methyl-4-oxo-3-p-tolyl-4H-quinolin-1-yl)-acetic acid N-methyl-hydrazide;
[3-(4-Fluoro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-acetic acid N-methyl-
hydrazide;
2-[3-(4-Fluoro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N-thiazol-2-yl-
acetamide;
2-[3-(4-Chloro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N-thiazol-2-yl-
acetamide;
2-[3-(4-Methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N-(4-
trifluoromethyl-phenyl)-acetamide;

48
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-(4-trifluoromethyl-phenyl)-
acetamide;
N-(4-Methoxy-phenyl)-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-
acetamide;
N-(4-Methoxy-phenyl)-2-[3-(4-methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-
1-yl]-acetamide;
2-[3-(4-Methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N-(5-methyl-2H-
pyrazol-3-yl)-acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-thiazol-2-yl-acetamide;
2-[3-(4-Methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N-thiazol-2-yl-
acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-(3-methyl-thiophen-2-
ylmethyl)-acetamide;
2-[3-(4-Methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N-(3-methyl-
isoxazol-5-yl)-acetamide;
2-[3-(4-Methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N-(5-methyl-
pyridin-2-yl)-acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-pyrimidin-2-yl-acetamide;
N-Furan-2-ylmethyl-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-
acetamide;
N-(2,5-Dimethyl-2H-pyrazol-3-yl)-2-[3-(4-methoxy-phenyl)-7-methyl-4-oxo-
4H-quinolin-1-yl]-acetamide;
N,N-Diethyl-2-[3-(4-methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-
acetamide;
3-(4-Methoxy-phenyl)-7-methyl-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-1H-quinolin-
4-one;
3-(4-Methoxy-phenyl)-7-methyl-1-(2-oxo-2-piperidin-1-yl-ethyl)-1H-quinolin-
4-one;
N-Ethyl-N-(2-hydroxy-ethyl)-2-[3-(4-methoxy-phenyl)-7-methyl-4-oxo-4H-
quinolin-1-yl]-acetamide;
N-(2-Hydroxy-ethyl)-2-[3-(4-methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-
yl]-N-propyl-acetamide;
N-Cyclopropylmethyl-2-[3-(4-methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-
1-yl]-N-propyl-acetamide;

49
N,N-Bis-(2-hydroxy-ethyl)-2-[3-(4-methoxy-phenyl)-7-methyl-4-oxo-4H-
quinolin-1-yl]-acetamide;
N,N-Diallyl-2-[3-(4-methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-
acetamide;
N-(3,5-Dimethyl-isoxazol-4-yl)-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-
yl)-acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-(1-methyl-1H-pyrazol-3-yl)-
acetamide;
N-(2,5-Dimethyl-2H-pyrazol-3-yl)-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-
yl)-acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-(5-methyl-pyridin-2-yl)-
acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-[1,3,4]thiadiazol-2-yl-
acetamide;
N-(4-Dimethylamino-phenyl)-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-
acetamide;
N-(3-Methyl-isoxazol-5-yl)-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-
acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-p-tolyl-acetamide;
2-[3-(4-Methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N-(1-methyl-1H-
pyrazol-3-yl)-acetamide;
1-[2-(2,5-Dimethyl-2,5-dihydro-pyrrol-1-yl)-2-oxo-ethyl]-3-(4-methoxy-
phenyl)-7-methyl-1H-quinolin-4-one;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-l-yl)-N-(5-methyl-2H-pyrazol-3-yl)-
acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-pyridin-2-ylmethyl-
acetamide;
N-(2-Acetyl-thiophen-3-yl)-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-
acetamide;
N-Ethyl-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-[1,3,4]thiadiazol-2-
yl-acetamide;
N-(2-Methyl-1H-indol-5-yl)-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-
acetamide;

50
1-[2-(3,6-Dihydro-2H-pyridin-1-yl)-2-oxo-ethyl]-7-methyl-3-phenyl-1H-
quinolin-4-one;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-(1H-pyrazol-3-yl)-
acetamide;
N-(4-Fluoro-phenyl)-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-
acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-(5-trifluoromethyl-
[1,3,4]thiadiazol-2-yl)-acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-quinolin-2-yl-acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-(2-methyl-2H-pyrazol-3-yl)-
acetamide;
N-(5-Cyclopropyl-2H-pyrazol-3-yl)-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-
1-yl)-acetamide;
N-Isoquinolin-3-yl-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetamide;
N-Indan-2-yl-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-(2-thiophen-2-yl-ethyl)-
acetamide;
7-Bromo-1-[2-(3,6-dihydro-2H-pyridin-1-yl)-2-oxo-ethyl]-3-phenyl-1H-
quinolin-4-one;
(7-Bromo-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetic acid hydrazide;
2-(7-Bromo-4-oxo-3-phenyl-4H-quinolin-1-yl)-N,N-dibutyl-acetamide;
7-Bromo-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-3-phenyl-1H-quinolin-4-one;
7-Bromo-1-(2-oxo-2-piperidin-1-yl-ethyl)-3-phenyl-1H-quinolin-4-one;
7-Bromo-1-[2-(2,6-dimethyl-morpholin-4-yl)-2-oxo-ethyl]-3-phenyl-1H-
quinolin-4-one;
N,N-Diallyl-2-(7-bromo-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetamide;
7-Bromo-1-(2-(2,5-dimethyl-2,5-dihydro-pyrrol-1-yl)-2-oxo-ethyl]-3-phenyl-
1H-quinolin-4-one;
2-(7-Bromo-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-cyclopropylmethyl-N-propyl-
acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-(5-nitro-thiazol-2-yl)-
acetamide;
N-Isoxazol-3-yl-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetamide;

51
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-(4-methyl-thiazol-2-yl)-
acetamide;
7-Bromo-1-(2-oxo-2-piperidin-1-yl-ethyl)-3-phenyl-1H-quinolin-4-one;
(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetic acid methyl ester;
(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetic acid;
[3-(4-Methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-acetic acid methyl
ester;
[3-(4-Methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-acetic acid;
(7-Bromo-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetic acid;
1-[2-(2,6-Dimethyl-morpholin-4-yl)-2-oxo-ethyl]-3-(4-methoxy-phenyl)-7-
methyl-1H-quinolin-4-one;
1-[2-(3,5-Dimethyl-piperidin-1-yl)-2-oxo-ethyl]-3-(4-methoxy-phenyl)-7-
methyl-1H-quinolin-4-one;
N-(6-Methoxy-pyrimidin-4-yl)-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-
acetamide;
1-[2-(4-Hydroxy-piperidin-1-yl)-2-oxo-ethyl]-7-methyl-3-phenyl-1H-quinolin-
4-one;
N-Isoxazol-3-yl-2-[3-(4-methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-
acetamide; and
1-[2-(4-Hydroxy-piperidin-1-yl)-2-oxo-ethyl]-3-(4-methoxy-phenyl)-7-methyl-
1H-quinolin-4-one; and
the pharmaceutically acceptable salts and hydrates thereof.
8. A process for preparing a-compound of formula (I) as defined in
claim 1, comprising reacting an intermediate compound of formula (VII):
<IMG>

52
wherein R1, R2, R3 and R4 are as defined for (I), with the appropriate 2-
bromo ethanone (XII):
<IMG>
wherein R5 is as defined in claim 1.
9. A process according,to claim 9 for preparing an amide compound of
formula (I), wherein R5 is NR6R7, comprising reacting an acid compound of
formula (I) as defined in claim 1, wherein R5 is OH, with the appropriate
amine R6R7NH (IX), wherein R6 and R7 are as defined in claim 1.
10. A process according to claim 9 for preparing an hydrazide compound
of formula (I), wherein R5 is N(R8)NH2, comprising reacting an ester
compound of formula (I), wherein R5 is OR9, with the appropriate hydrazine
of formula NH2NHR8 (X), wherein R8 is as defined in claim 1.
11. Use of a compound according to any one of claims 1 to 7 for the
preparation of a medicament for treating or preventing diseases associated
with the GABA A receptor modulation, anxiety, epilepsy, sleep disorders or
insomnia, for inducing sedation-hypnosis, anaesthesia or muscle relaxation
or for modulating the necessary time to induce sleep and its duration in a
human or non-human mammal in need thereof.
12. The use of claim 16 wherein the GABA A receptor is the .alpha.1-GABA A
receptor or the .alpha.2-GABA A receptor.
13. A pharmaceutical composition comprising a therapeutically effective
amount of a compound as defined in any one of claims 1 to 7, together with
appropriate amounts of pharmaceutical excipients or carriers.

53
14. A method for treating or preventing diseases associated with the
GABA A receptor modulation in a human or non-human mammal in need
thereof, which comprises administering to said mammal an effective
amount of a compound of formula I as claimed in claim 1, or a compound of
formula (I):
<IMG>
wherein
R1 and R2 are independently selected from the group consisting of
hydrogen, alkyl(C1-C6), Oalkyl(C1-C6), halogen and phenyl;
R3 and R4 are independently selected from the group -consisting of
hydrogen and phenyl optionally substituted by alkyl(C1-C6), halogen and
Oalkyl(C1-C6);
R5 is selected from the group consisting of R5 is selected from the group
consisting of NR6R7, N(R8)NH2 and a heteroaryl ring selected from the
group consisting of pyridyl, furyl, thienyl, oxazolyl, isoxazolyl, imidazolyl,
pyrrolyl, pyrazolyl, pyrimidinyl and pyrazinyl, wherein each heteroaryl ring
contains one or two optional alkyl(C1-C6) substituents;
R6 and R7 are independently selected from the group consisting of
hydrogen; alkyl(C1-C6); alkenyl(C2-C6); cycloalkyl(C3-C6)alkyl(C1-C6);
hydroxyalkyl(C1-C6); heteroaryl selected from the group consisting of
pyridyl, pyrimidinyl, oyrazinyl, thiazolyl, benzothiazolyl, oxazolyl,

54
benzoxazolyl, isoxazolyl, benzisoxazolyl, pyrazolyl, furyl, benzofuryl,
thienyl, benzothienyl, thiadiazolyl, pyrrolyl, imidazolyl, benzimidazolyl,
indolyl, quinolyl and isoquinolyl, wherein each heteroaryl contains one or
two optional substituents independently selected from the group consisting
of alkyl(C1-C6), Oalkyl(C1-C6), haloalkyl(C1-C6), cycloalkyl(C3-C6), NO2 and
COalkyl(C1-C6); thienylalkyl(C1-C6), furylalkyl(C1-C6), pyridylalkyl(C1-C6);
and aryl selected from the group consisting of phenyl and indanyl, wherein
each aryl contains one or two optional substituents selected from the group
consisting of alkyl(C1-C6), haloalkyl(C1-C6), halogen, Ndialkyl(C1-C6),
NHalkyl(C1-C6), Oalkyl(C1-C6), NO2, CN, OH, NH2, COOH, COalkyl(C1-C6),
COOalkyl(C1-C6), CONHalkyl(C1-C6), CONdialkyl(C1-C6) and COphenyl;
or R6 and R7 can form, together with the nitrogen atom to which they are
attached, a heterocycle selected from pyrrolidine, 3-pyrroline, 1,2,3,6-
tetrahydropyridine, piperidine, morpholine, thiomorpholine and piperazine,
wherein each heterocycle contains one, two, three or four optional
substituents selected from the group consisting of OH, alkyl(C1-C6) and
COalkyl(C1-C6);
R8 is selected from the group consisting of hydrogen and alkyl(C1-C6); and
R9 is alkyl(C1-C6);
with the proviso that R3 and R4 cannot be hydrogen simultaneously; or a
compound of claim 7;
or a pharmaceutically acceptable salt thereof or a hydrate thereof.
15. The method of claim 14, wherein the GABA A receptor is the .alpha.1-
GABA A receptor.
16. The method of claim 14 wherein the GABA A receptor is the .alpha.2-
GABA A receptor.

55
17. A method for treating or preventing anxiety in a human or non-
human mammal in need thereof, which comprises administering to said
mammal an effective amount of a compound of formula I as defined in
claim 14, or a compound of claim 7 or a pharmaceutically acceptable salt or
hydrate thereof.
18. A method for treating or preventing epilepsy in a human or non-
human mammal in need thereof, which comprises administering to said
mammal an effective amount of a compound of formula I as defined in
claim 14, or a compound of claim 7 or a pharmaceutically acceptable salt or
hydrate thereof.
19. A method for treating or preventing sleep disorders in a human or
non-human mammal in need thereof, which comprises administering to said
mammal an effective amount of a compound of formula I as defined in
claim 14, or a compound of claim 7 or a pharmaceutically acceptable salt or
hydrate thereof.
20. A method for treating or preventing insomnia in a human or non-
human mammal in need thereof, which comprises administering to said
mammal an effective amount of a compound of formula I as defined in
claim 14, or a compound of claim 7 or a pharmaceutically acceptable salt or
hydrate thereof.
21. A method for inducing sedation hypnosis in a human or non-human
mammal in need thereof, which comprises administering to said mammal
an effective amount of a compound of formula I as defined in claim 14, or a
compound of claim 7 or a pharmaceutically acceptable salt or hydrate
thereof.
22. A method for inducing anesthesia in a human or non-human
mammal in need thereof, which comprises administering to said mammal
an effective amount of a compound of formula I as defined in claim 14, or a

56
compound of claim 7 or a pharmaceutically acceptable salt or hydrate
thereof.
23. A method for modulating the necessary time to induce sleep and its
duration in a human or non-human mammal in need thereof, which
comprises administering to said mammal an effective amount of a
compound of formula I as defined in claim 14, or a compound of claim 7 or
a pharmaceutically acceptable salt or hydrate thereof.
24. A method for inducing muscle relaxation in a human or non-human
mammal in need thereof, which comprises administering to said mammal
an effective amount of a compound of formula I as defined in claim 14, or a
compound of claim 7 or a pharmaceutically acceptable salt or hydrate
thereof.
25. The use of a 1H-quinolin-one compound of formula (I):
<IMG>
wherein
R1 and R2 are independently selected from the group consisting of
hydrogen, alkyl(C1-C6), Oalkyl(C1-C6), halogen and phenyl;
R3 and R4 are independently selected from the group consisting of
hydrogen and phenyl optionally substituted by alkyl(C1-C6), halogen and
Oalkyl(C1-C6);

57
R5 is selected from the group consisting of R5 is selected from the group
consisting of NR6R7, N(R8)NH2 and a heteroaryl ring selected from the
group consisting of pyridyl, furyl, thienyl, oxazolyl, isoxazolyl, imidazolyl,
pyrrolyl, pyrazolyl, pyrimidinyl and pyrazinyl, wherein each heteroaryl ring
contains one or two optional alkyl(C1-C6) substituents;
R6 and R7 are independently selected from the group consisting of
hydrogen; alkyl(C1-C6); alkenyl(C2-C6); cycloalkyl(C3-C6)alkyl(C1-C6);
hydroxyalkyl(C1-C6); heteroaryl selected from the group consisting of
pyridyl, pyrimidinyl, pyrazinyl, thiazolyl, benzothiazolyl, oxazolyl,
benzoxazolyl, isoxazolyl, benzisoxazolyl, pyrazolyl, furyl, benzofuryl,
thienyl, benzothienyl, thiadiazolyl, pyrrolyl, imidazolyl, benzimidazolyl,
indolyl, quinolyl and isoquinolyl, wherein each heteroaryl contains one or
two optional substituents independently selected from the group consisting
of alkyl(C1-C6), Oalkyl(C1-C6), haloalkyl(C1-C6), cycloalkyl(C3-C6), NO2 and
COalkyl(C1-C6); thienylalkyl(C1-C6), furylalkyl(C1-C6), pyridylalkyl(C1-C6);
and aryl selected from the group consisting of phenyl and indanyl, wherein
each aryl contains one or two optional substituents selected from the group
consisting of alkyl(C1-C6), haloalkyl(C1-C6), halogen, Ndialkyl(C1-C6),
NHalkyl(C1-C6), Oalkyl(C1-C6), NO2, CN, OH, NH2, COOH, COalkyl(C1-C6),
COOalkyl(C1-C6), CONHalkyl(C1-C6), CONdialkyl(C1-C6) and COphenyl;
or R6 and R7 can form, together with the nitrogen atom to which they are
attached, a heterocycle selected from pyrrolidine, 3-pyrroline, 1,2,3,6-
tetrahydropyridine, piperidine, morpholine, thiomorpholine and piperazine,
wherein each heterocycle contains one, two, three or four optional
substituents selected from the group consisting of OH, alkyl(C1-C6) and
COalkyl(C1-C6);
R8 is selected from the group consisting of hydrogen and alkyl(C1-C6); and
R9 is alkyl(C1-C6);

58
with the proviso that R3 and R4 cannot be hydrogen simultaneously; or of a
compound of claim 7;
or a pharmaceutically acceptable salt or hydrate thereof, or
for the preparation of a medicament for treating or preventing diseases
associated with the GABA A receptor modulation, anxiety, epilepsy, sleep
disorders or insomnia, for inducing sedation-hypnosis, anaesthesia or
muscle relaxation or for modulating the necessary time to induce sleep and
its duration in a human or non-human mammal in need thereof.
26. A 1H-quinoline-one compound as defined in claim 25 or of a
compound of claim 7 for use in the treatment or prevention of diseases
associated with the GABA A receptor modulation, anxiety, epilepsy, sleep
disorders or insomnia, for inducing sedation-hypnosis, anaesthesia or
muscle relaxation or for modulating the necessary time to induce sleep and
its duration in a human or non-human mammal in need thereof.
27. The 1H-quinoline-one compound of claim 26, wherein the GABA A
receptor is the .alpha.1-GABA A receptor or the .alpha.2-GABA A receptor.

Description

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR,
PROCESSES, USES AND COMPOSITIONS
TECHNICAL FIELD
This invention is directed to a new class of agents with affinity for GABAA
receptor. The invention concerns specifically new 1 H-quinolin-4-one
compounds which are useful for treating or preventing anxiety, epilepsy and
sleep disorders including insomnia, and for inducing sedation-hypnosis,
anaesthesia, sleep and muscle relaxation.
BACKGROUND OF THE INVENTION
GABAA receptor (y-aminobutyric acidA) is a pentameric protein which forms
a membrane ion channel. GABAA receptor is implicated in the regulation of
sedation, anxiety, muscle tone, epileptogenic activity and memory
functions. These actions are due to defined subunits of GABAA receptor,
particularly the al- and a2-subunits.
Sedation is modulated by the al-subunit. Zolpidem is characterized by a
high affinity for the al-receptors and its sedative and hypnotic action is
mediated by these receptors in vivo. Similarly, the hypnotic action of
zaleplon is also mediated by the ai-receptors.
The anxiolytic action of diazepam is mediated by the enhancement of
GABAergic transmission in a population of neurons expressing the a2-
receptors. This indicates that the a2-receptors are highly specific targets
for
the treatment of anxiety.
Muscle relaxation in diazepam is mainly mediated by a2-receptors, since
these receptors exhibit a highly specific expression in spinal cord.

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
2
The anticonvulsant effect of diazepam is partly due to ai-receptors. In
diazepam, a memory-impairing compound, anterograde amnesia is
mediated by al-receptors.
GABAA receptor and its al- and a2-subunits have been widely reviewed by
H. Mohler et al. (J. Pharmacol. Exp. Ther., 300, 2-8, 2002); H. Mohler et al.
(Curr. Opin. Pharmacol., 1, 22-25, 2001); U. Rudolph et al. (Nature, 401,
796-800, 1999); and D.J. Nutt et al. (Br. J. Psychiatry, 179, 390-396, 2001).
Diazepam and other classical benzodiazepines are extensively used as
anxiolytic agents, hypnotic agents, anticonvulsants and muscle relaxants.
Their side effects include anterograde amnesia, decrease in motor activity
and potentiation of ethanol effects.
In this context, the compounds of this invention are ligands of al- and a2-
GABAA receptor for their clinical application in sleep disorders, preferably
insomnia, anxiety and epilepsy.
Insomnia is a highly prevalent disease. Its chronicity affects 10% of the
population and 30% when transitory insomnia is computed as well.
Insomnia describes the trouble in getting to sleep or staying asleep and is
associated with next-day hangover effects such as weariness, lack of
energy, low concentration and irritability. The social and health impact of
this complaint is important and results in evident socioeconomic
repercussions.
Pharmacological therapy in the management of insomnia firstly included
barbiturates and chloral hydrate, but these drugs elicit numerous known
adverse effects, for example, overdose toxicity, metabolic induction, and
enhanced dependence and tolerance. In addition, they affect the
architecture of sleep by decreasing above all the duration and the number
of REM sleep stages. Later, benzodiazepines meant an important

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
3
therapeutic advance because of their lower toxicity, but they still showed
serious problems of dependence, muscle relaxation, amnesia and rebound
insomnia following discontinuation of medication.
The latest known therapeutic approach has been the introduction of non-
benzodiazepine hypnotics, such as pyrrolo[3,4-b]pyrazines (zopiclone),
imidazo[1,2-a] pyridines (zolpidem) and, finally, pyrazolo[1,5-a] pyrimidines
(zaleplon). Later, two new pyrazolo[1,5-a] pyrimidines, indiplon and
ocinaplon, have entered into development, the latter with rather anxiolytic
action. All these compounds show a rapid sleep induction and have less
next-day hangover effects, lower potential for abuse and lower risk of
rebound insomnia than benzodiazepines. The mechanism of action of these
compounds is the alosteric activation of GABAA receptor through its binding
to benzodiazepine binding site (C. F. P. George, The Lancet, 358, 1623-
1626, 2001). While benzodiazepines are unspecific ligands at GABAA
receptor binding site, zolpidem and zaleplon show a greater selectivity for
al-subunit. Notwithstanding that, these drugs still affect the architecture of
sleep and may induce dependence in long-term treatments.
Research for new active compounds in the management of insomnia
answers an underlying health need, because even recently introduced
hypnotics still affect the architecture of sleep and may induce dependence
in long-term treatments.
It is therefore desirable to focus on the development of new hypnotic agents
with a lower risk of side effects.
The present invention is directed to a new class of 1 H-quinolin-4-one
compounds, specifically a new chemotype consisting of phenyl-substituted
N-acetyl-1 H-quinolin-4-one, which is active versus GABAA receptor and,
particularly, versus its al- and a2-subunits. No related compounds

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
4
belonging to this chemotype have been disclosed to present with ligand
GABAA receptor or any other central nervous system activity.
Compounds containing the 1 H-quinolin-4-one core have been disclosed for
other purposes. Thus, EP 856255 discloses the use of some 1 H-quinolin-
4-ones as marine antifouling agents, WO 2001012607 discloses some
other 1 H-quinolin-4-ones which increase the activity of cytotoxic agents,
and finally WO 2002022074 discloses the preparation of some 1 H-3-
phenyl-quinolin-4-ones as intimal neoproliferation inhibitors.
The compounds of the present invention have a high affinity for al- and a2-
GABAA receptors. The in vitro activities shown by these compounds are
consistent with those in vivo results obtained in sedation-hypnosis tests.
Consequently, the compounds of this invention are useful in the treatment
and prevention of all those diseases mediated by GABAA receptor al- and
a2-subunits. Non-limitative examples of such diseases are sleep disorders,
preferably insomnia, anxiety and epilepsy. Non-limitative examples of the
relevant indications of the compounds of this invention are all those
diseases or conditions, such as insomnia or anesthesia, in which an
induction of sleep, an induction of sedation or an induction of muscle
relaxation are needed.
SUMMARY OF THE INVENTION
The present invention relates to a compound of formula (I):
Rl O
R3
I / I
R2 N R4
O
R5
(I)

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
and pharmaceutically acceptable salts and hydrates thereof, which are
ligands of GABAA receptor.
5 It is another object of this invention to provide synthetic procedures for
preparing the compounds of formula (I). Novel methods of treating or
preventing diseases associated with GABAA receptor modulation such as
anxiety, epilepsy and sleep disorders including insomnia, and for inducing
sedation-hypnosis, anesthesia, sleep and muscle relaxation by
administering a therapeutically effective amount of said compounds are
also within the scope of the invention.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a compound of formula (I):
Rl O
R3
I / I
R2 N R4
O
R5
(I)
wherein R, and R2 are independently selected from the group consisting of
hydrogen, alkyl(Cl-C6), Oalkyl(Cl-C6), halogen and phenyl; R3 and R4 are
independently selected from the group consisting of hydrogen and phenyl
optionally substituted by alkyl(Cl-C6), halogen and Oalkyl(Cl-C6); R5 is
selected from the group consisting of NR6R7, N(R8)NH2, OH, OR9, and a
heteroaryl ring selected from the group consisting of pyridyl, furyl, thienyl,
oxazolyl, isoxazolyl, imidazolyl, pyrrolyl, pyrazolyl, pyrimidinyl and
pyrazinyl,
wherein each heteroaryl ring contains one or two optional alkyl(Cl-C6)
substituents; R6 and R7 are independently selected from the group

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
6
consisting of hydrogen; alkyl(Cl-C6); alkenyl(C2-C6); cycloalkyl(C3-
C6)alkyl(Cl-C6); hydroxyalkyl(Cl-C6); heteroaryl selected from the group
consisting of pyridyl, pyrimidinyl, pyrazinyl, thiazolyl, benzothiazolyl,
oxazolyl, benzoxazolyl, isoxazolyl, benzisoxazolyl, pyrazolyl, furyl,
benzofuryl, thienyl, benzothienyl, thiadiazolyl, pyrrolyl, imidazolyl,
benzimidazolyl, indolyl, quinolyl and isoquinolyl, wherein each heteroaryl
contains one or two optional substituents independently selected from the
group consisting of alkyl(Cl-C6), Oalkyl(Cl-C6), haloalkyl(Cl-C6),
cycloalkyl(C3-C6), NO2 and COalkyl(Cl-C6); thienylalkyl(Cl-C6),
furylalkyl(Cl-C6), pyridylalkyl(Cl-C6); and aryl selected from the group
consisting of phenyl and indanyl, wherein each aryl contains one or two
optional substituents selected from the group consisting of alkyl(Cl-C6),
haloalkyl(Cl-C6), halogen, Ndialkyl(Cl-C6), NHalkyl(Cl-C6), Oalkyl(Cl-C6),
NO2, CN, OH, NH2, COOH, COalkyl(Cl-C6), COOalkyl(Cl-C6),
CONHalkyl(Cl-C6), CONdialkyl(Cl-C6) and COphenyl; or R6 and R7 can
form, together with the nitrogen atom to which they are attached, a
heterocycle selected from pyrrolidine, 3-pyrroline, 1,2,3,6-
tetrahydropyridine, piperidine, morpholine, thiomorpholine and piperazine,
wherein each heterocycle contains one, two, three or four optional
substituents selected from the group consisting of OH, alkyl(Cl-C6) and
COalkyl(Cl-C6); R8 is selected from the group consisting of hydrogen and
alkyl(Cl-C6); and R9 is alkyl(Cl-C6); with the proviso that R3 and R4 cannot
be hydrogen simultaneously; and pharmaceutically acceptable salts and
hydrates thereof.
In a preferred embodiment R' is selected from the group consisting of
hydrogen, alkyl(Cl-C6), Oalkyl(Cl-C6), halogen and phenyl; R2 is selected
from the group consisting of hydrogen, alkyl(Cl-C6), halogen and phenyl;
and R3, R4, R5, R6 ,R,, R8 and R9 are as defined above.
In another preferred embodiment R5 is selected from the group consisting
of NR6R7, N(R8)NH2 and a heteroaryl ring selected from the group

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
7
consisting of pyridyl, furyl, thienyl, oxazolyl, isoxazolyl, imidazolyl,
pyrrolyl,
pyrazolyl, pyrimidinyl and pyrazinyl, wherein each heteroaryl ring contains
one or two optional alkyl(Cl-C6) substituents; R6 and R7 are as defined
above, with the proviso that R6 and R7 are not NH2, NH(Cj-C4 alkyl) or
N(Cl-C4 alkyl)2; and Ri, R2, R3, R4 and R8 are as defined above.
In another preferred embodiment, R, and R2 are independently selected
from hydrogen, alkyl(Cl-C6), halogen, in particular bromine, and phenyl.
In another preferred embodiment, R, and R2 are independently selected
from the group consisting of hydrogen, methyl, bromine and phenyl.
In another preferred embodiment, R3 and R4 are independently selected
from the group consisting of hydrogen, phenyl, 4-fluorophenyl, 4-
chlorophenyl, p-tolyl and 4-methoxyphenyl.
In another preferred embodiment, R5 is selected from the group consisting
of OH, methoxy, ethoxy, NHNH2, N(methyl)NH2, 2-pyridyl, 3-pyridil, 4-
pyridyl, 2-pyrazinyl, 5-methyl-2-furyl, 2-thienyl and 2,4-dimethyl-5-oxazolyl.
In another preferred embodiment, R5 is NR6R7 and R6 and R7 are
independently selected from hydrogen, alkyl(Cl-C6); alkenyl(C2-C6);
cycloalkyl(C3-C6)alkyl(Cj-C6); hydroxyalkyl(Cl-C6); heteroaryl selected from
the group consisting of pyridyl; pyrimidinyl, optionally substituted with one
or two substituents independently selected from Oalkyl(Cl-C6) and OH;
pyrazinyl; thiazolyl, optionally substituted with one or two substituents
independently selected from alkyl(Cl-C6) and NO2 ; benzothiazolyl;
oxazolyl, optionally substituted with one or two alkyl(Cl-C6); benzoxazolyl;
isoxazolyl, optionally substituted with one or two alkyl(Cl-C6);
benzisoxazolyl; pyrazolyl, optionally substituted with one or two substituents
independently selected from alkyl(Cl-C6) and cycloalkyl(Cl-C6); furyl,
optionally substituted with one or two alkyl(Cl-C6); benzofuryl; thienyl,

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
8
optionally substituted with one or two COalkyl(Cl-C6); benzothienyl;
thiadiazolyl, optionally substituted with one or two haloalkyl(Cl-C6);
pyrrolyl,
optionally substituted with one or two alkyl(Cl-C6); imidazolyl;
benzimidazolyl; indolyl, optionally substituted with one or two alkyl(Cl-C6);
quinolyl; and isoquinolyl; thienylalkyl(Cl-C6), furylalkyl(Cl-C6),
pyridylalkyl(Cl-C6); phenyl, optionally substituted with one or two
substituents independently selected from alkyl(Cl-C6), haloalkyl(Cl-C6),
Oalkyl(Cl-C6), halogen, NHalkyl(Cl-C6), and Ndialkyl(Cl-C6); and indanyl;
or R6 and R7 can form, together with the nitrogen atom to which they are
attached, a heterocycle selected from pyrrolidine, 3-pyrroline, optionally
substituted with one or two alkyl(Cl-C6), 1,2,3,6-tetrahydropyridine,
piperidine, optionally substituted with one or two substituents independently
selected from alkyl(Cl-C6) and OH, morpholine, optionally substituted with
one or two alkyl(Cl-C6), thiomorpholine and piperazine, optionally
substituted with one or two substituents independently selected from
alkyl(Cl-C6) and COalkyl(Cl-C6).
In another preferred embodiment, R5 is NR6R7 and R6 and R7 are
independently selected from the group consisting of hydrogen, ethyl, propyl,
iso-propyl, butyl, hexyl, allyl, hydroxyethyl, cyclopropylmethyl, 1,3,4-
thiadiazol-2-yl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-3-pyrazolyl, 2,5-dimethyl-
3-pyrrolinyl, 1,2,3,6-tetrahydropiperidinyl, 2,5-dimethyl-3-pyrazolyl, 2-
acetyl-
3-thienyl, 2-indanyl, 2-methyl-3-pyrazolyl, 2-methyl-5-indolyl, 2-pirazinyl, 2-
pyrimidinyl, 2-quinolyl, 2-thiazolyl, 3,5-isoxazol-4-yl, 3-isoxazolyl, 3-
methyl-
2-thienylmethyl, 3-methyl-5-isoxazolyl, 3-methyl-6-pyridyl, 3-methylisoxazol-
5-yl, 3-oxazolyl, 3-pyrazolyl, 1,3,4-thiadiazol-2-yl, 4-methyl-2-thiazolyl, 5-
trifluoromethyl-1,3,4-thiadiazol-2-yl, 5-cyclopropyl-3-pyrazolyl, 5-methyl-2-
pyridyl, 5-methyl-3-pyrazolyl, 5-methyl-isoxazol-3-yl, 5-nitro-2-thiazol-2-yl,
6-methoxy-4-pyrimidinyl, 2-furylmethyl, 2-pyridylmethyl, 2-thienylethyl,
phenyl, p-tolyl, 4-trifluoromethylphenyl, 4-dimethylaminophenyl, 4-
fluorophenyl and 4-methoxyphenyl; or R6 and R7 form, together with the
nitrogen atom to which they are attached, pyrrole, 2,5-dimethyl-3-pyrroline,

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
9
piperidine, 1,2,3,6-tetrahydropyridine, 4-hydroxypiperidine, 3,5-
dimethylpiperidine, morpholine, 2,6-dimethylmorpholine, 4-methylpiperazine
and 4-acetylpiperazine.
The term "pharmaceutically acceptable salts" means salts which are
acceptable for administration to a patient, such as a mammal (e.g., salts
having acceptable mammalian safety for a given dosage regime). Such
salts can be derived from pharmaceutically acceptable inorganic or organic
bases and from pharmaceutically acceptable inorganic or organic acids.
Salts derived from pharmaceutically acceptable inorganic bases include
ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic,
manganous, potassium, sodium, zinc and the like. Particularly preferred are
ammonium, calcium, magnesium, potassium and sodium salts. Salts
derived from pharmaceutically acceptable organic bases include salts of
primary, secondary and tertiary amines, including substituted amines, cyclic
amines, naturally-occurring amines and the like, such as arginine, betaine,
caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-
diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine,
ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine,
glucosamine, histidine, hydrabamine, isopropylamine, lysine,
methylglucamine, morpholine, piperazine, piperadine, polyamine resins,
procaine, purines, theobromine, triethylamine, trimethylamine,
tripropylamine, tromethamine and the like. Salts derived from
pharmaceutically acceptable acids include acetic, ascorbic,
benzenesulfonic, benzoic, camphosulfonic, citric, ethanesulfonic, edisylic,
fumaric, gentisic, gluconic, glucoronic, glutamic, hippuric, hydrobromic,
hydrochloric, isethionic, lactic, lactobionic, maleic, malic, mandelic,
methanesulfonic, mucic, naphthalenesulfonic, naphthalene-1,5-disulfonic,
naphthalene-2,6-disulfonic, nicotinic, nitric, orotic, pamoic, pantothenic,
phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic, xinafoic and the
like. Particularly preferred are citric, hydrobromic, hydrochloric,
isethionic,
maleic, naphthalene-1,5-disulfonic, phosphoric, sulfuric and tartaric acids.

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
Halogen or halo means F, Cl, Br, and I.
Alkyl(Cl-C6) means a straight or branched alkyl chain with 1 to 6 carbon
5 atoms such as methyl, ethyl, n-propyl, I-propyl, n-butyl, sec-butyl, 1-
butyl, t-
butyl, n-pentyl and n-hexyl.
Alkenyl(C2-C6) means a straight or branched alkenyl chain with 2 to 6
carbon atoms such as allyl.
Specific compounds of formula (I) are selected from the group consisting of:
5-Methyl-1 -(2-morpholin-4-yl-2-oxo-ethyl)-2-phenyl-1 H-quinolin-4-one;
N,N-Diethyl-2-(7-methyl-4-oxo-2-phenyl-4H-quinolin-1 -yl)-acetamide;
7-Methyl-1 -(2-morpholin-4-yl-2-oxo-ethyl)-2-phenyl-1 H-quinolin-4-one;
(7-Methyl-4-oxo-2-phenyl-4H-quinolin-1-yl)-acetic acid ethyl ester;
N,N-Dibutyl-2-(7-methyl-4-oxo-2-phenyl-4H-quinolin-1 -yl)-acetamide;
N,N-Diisopropyl-2-(5-methyl-4-oxo-2-phenyl-4H-quinolin-1 -yl)-
acetamide;
5-Methyl-1 -(2-oxo-2-pyrrolidin-1 -yl-ethyl)-2-phenyl-1 H-quinolin-4-one;
2-(7-Methyl-4-oxo-2-phenyl-4H-quinolin-1 -yl)-N,N-dipropyl-acetamide;
N,N-Dihexyl-2-(5-methyl-4-oxo-2-phenyl-4H-quinolin-1 -yl)-acetamide;
5-Methyl-1 -(2-oxo-2-piperidin-1 -yl-ethyl)-2-phenyl-1 H-quinolin-4-one;
5-Methyl-1 -(2-oxo-2-pyrrolidin-1 -yl-ethyl)-2-phenyl-1 H-quinolin-4-one;
7-Methyl-1 -(2-oxo-2-pyrrolidin-1 -yl-ethyl)-2-phenyl-1 H-quinolin-4-one;
N,N-Dibutyl-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-N,N-dipropyl-acetamide;
7-Methyl-1 -(2-oxo-2-piperidin-1 -yl-ethyl)-3-phenyl-1 H-quinolin-4-one;
N,N-Dihexyl-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-acetamide;
N,N-Diethyl-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-acetamide;
7-Methyl-1 -(2-oxo-2-pyrrolidin-1 -yl-ethyl)-3-phenyl-1 H-quinolin-4-one;
7-Methyl-1 -(2-morpholin-4-yl-2-oxo-ethyl)-3-phenyl-1 H-quinolin-4-one;

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
11
N,N-Diisopropyl-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-
acetamide;
N,N-Dihexyl-2-(5-methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-acetamide;
5-Methyl-1 -(2-oxo-2-piperidin-1 -yl-ethyl)-3-phenyl-1 H-quinolin-4-one;
5-Methyl-1 -(2-morpholin-4-yl-2-oxo-ethyl)-3-phenyl-1 H-quinolin-4-one;
N,N-Diethyl-2-(5-methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-acetamide;
N,N-Dibutyl-2-(5-methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-acetamide;
7-Methyl-1 -(2-oxo-2-pyridin-3-yl-ethyl)-3-phenyl-1 H-quinolin-4-one;
7-Methyl-1 -(2-oxo-2-thiophen-2-yl-ethyl)-3-phenyl-1 H-quinolin-4-one;
7-Methyl-1 -(2-oxo-2-pyridin-2-yl-ethyl)-3-phenyl-1 H-quinolin-4-one;
7-Methyl-1 -(2-oxo-2-pyridin-4-yl-ethyl)-3-phenyl-1 H-quinolin-4-one;
1-[2-(4-Acetyl-piperazin-1 -yl)-2-oxo-ethyl]-7-methyl-3-phenyl-1 H-
quinolin-4-one;
7-Methyl-1 -[2-(5-methyl-furan-2-yl)-2-oxo-ethyl]-3-phenyl-1 H-quinolin-4-
one;
1-[2-(2,6-Dimethyl-morpholin-4-yl)-2-oxo-ethyl]-7-methyl-3-phenyl-1 H-
quinolin-4-one;
1-[2-(2,4-Dimethyl-oxazol-5-yl)-2-oxo-ethyl]-7-methyl-3-phenyl-1 H-
quinolin-4-one;
7-Methyl-1 -(2-oxo-2-pyrazin-2-yl-ethyl)-3-phenyl-1 H-quinolin-4-one;
7-Methyl-1 -[2-(4-methyl-piperazin-1 -yl)-2-oxo-ethyl]-3-phenyl-1 H-
quinolin-4-one;
2-[3-(4-Methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1 -yl]-N,N-dipropyl-
acetamide;
2-[3-(4-Chloro-phenyl)-7-methyl-4-oxo-4H-quinolin-1 -yl]-N,N-dipropyl-
acetamide;
2-(7-Methyl-4-oxo-3-p-tolyl-4H-quinolin-1 -yl)-N,N-dipropyl-acetamide;
N-Cyclopropylmethyl-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-l-yl)-N-
propyl-acetamide;
1-[2-(3,5-Dimethyl-piperidin-1 -yl)-2-oxo-ethyl]-7-methyl-3-phenyl-1 H-
quinolin-4-one;

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
12
1-[2-(3,6-Dihydro-2H-pyridin-1-yl)-2-oxo-ethyl]-7-methyl-3-phenyl-1 H-
quinolin-4-one;
1-[2-(2,5-Dimethyl-2,5-dihydro-pyrrol-1-yl)-2-oxo-ethyl]-7-methyl-3-
phenyl-1 H-quinolin-4-one;
N,N-Diallyl-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetamide;
2-(7-Bromo-4-oxo-3-phenyl-4H-quinolin-1 -yl)-N,N-dipropyl-acetamide;
2-(5-Bromo-4-oxo-3-phenyl-4H-quinolin-1 -yl)-N,N-dipropyl-acetamide;
2-(4-Oxo-3,7-diphenyl-4H-quinolin-1 -yl)-N,N-dipropyl-acetamide;
2-(4-Oxo-3-phenyl-4H-quinolin-1 -yl)-N,N-dipropyl-acetamide;
2-(4-Oxo-3,5-diphenyl-4H-quinolin-1 -yl)-N,N-dipropyl-acetamide;
(7-Methyl-4-oxo-3-p-tolyl-4H-quinolin-1 -yl)-acetic acid methyl ester;
(7-Methyl-4-oxo-3-p-tolyl-4H-quinolin-1 -yl)-acetic acid;
[3-(4-Chloro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-acetic acid methyl
ester;
[3-(4-Fluoro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-acetic acid methyl
ester;
[3-(4-Fluoro-phenyl)-7-methyl-4-oxo-4H-quinolin-1 -yl]-acetic acid;
2-[3-(4-Chloro-phenyl)-7-methyl-4-oxo-4H-quinolin-1 -yl]-N-phenyl-
acetamide;
2-[3-(4-Chloro-phenyl)-7-methyl-4-oxo-4H-quinolin-1 -yl]-N-pyrazin-2-yl-
acetamide;
[3-(4-Chloro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-acetic acid;
[3-(4-Chloro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-acetic acid
hydrazide;
2-(7-Methyl-4-oxo-3-p-tolyl-4H-quinolin-1 -yl)-N-phenyl-acetamide;
2-[3-(4-Fluoro-phenyl)-7-methyl-4-oxo-4H-quinolin-1 -yl]-N-phenyl-
acetamide;
2-(7-Methyl-4-oxo-3-p-tolyl-4H-quinolin-1 -yl)-N-thiazol-2-yl-acetamide;
N-(5-Methyl-isoxazol-3-yl)-2-(7-methyl-4-oxo-3-p-tolyl-4H-quinolin-l-yl)-
acetamide;
[3-(4-Fluoro-phenyl)-7-methyl-4-oxo-4H-quinolin-1 -yl]-acetic acid
hydrazide;

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
13
(7-Methyl-4-oxo-3-p-tolyl-4H-quinolin-1-yl)-acetic acid hydrazide;
2-[3-(4-Chloro-phenyl)-7-methyl-4-oxo-4H-quinolin-1 -yl]-N-(5-methyl-
isoxa zo I-3-y1)-a ceta m i d e;
2-[3-(4-Fluoro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N-(5-methyl-
isoxazol-3-yl)-acetamide;
N-Ethyl -N-(2-hyd roxy-ethyl )-2-(7-methyl-4-oxo-3-phenyl -4 H-q u i nol i n-1-
yl )-acetam ide;
N-(2-Hydroxy-ethyl)-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-
propyl-acetamide;
N,N-Diallyl-2-(5-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetamide;
N-(2-Hydroxy-ethyl)-2-(5-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-
propyl-acetamide;
(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetic acid;
(5-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetic acid;
[3-(4-Chloro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-acetic acid N-
methyl-hydrazide;
(7-Methyl-4-oxo-3-p-tolyl-4H-quinolin-1-yl)-acetic acid N-methyl-
hydrazide;
[3-(4-Fluoro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-acetic acid N-
methyl-hydrazide;
2-[3-(4-Fluoro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N-thiazol-2-yl-
acetamide;
2-[3-(4-Chloro-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N-thiazol-2-yl-
acetamide;
2-[3-(4-Methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N-(4-
trifluoromethyl-phenyl)-acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-(4-trifluoromethyl-
phenyl)-acetamide;
N-(4-Methoxy-phenyl)-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-
acetamide;
N-(4-Methoxy-phenyl)-2-[3-(4-methoxy-phenyl)-7-methyl-4-oxo-4H-
quinolin-1-yl]-acetamide;

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
14
2-[3-(4-Methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1 -yl]-N-(5-methyl-
2H-pyrazol-3-yl )-acetam id e;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-thiazol-2-yl-acetamide;
2-[3-(4-Methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N-thiazol-2-yl-
acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-(3-methyl-thiophen-2-
ylmethyl)-acetamide;
2-[3-(4-Methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1 -yl]-N-(3-methyl-
isoxa zo I-5-y1)-a ceta m i d e;
2-[3-(4-Methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-N-(5-methyl-
pyridin-2-yl)-acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-pyrimidin-2-yl-
acetamide;
N-Furan-2-ylmethyl-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-
acetamide;
N-(2,5-Dimethyl-2H-pyrazol-3-yl)-2-[3-(4-methoxy-phenyl)-7-methyl-4-
oxo-4H-quinolin-1-yl]-acetamide;
N,N-Diethyl-2-[3-(4-methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-
acetamide;
3-(4-Methoxy-phenyl)-7-methyl-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-1 H-
quinolin-4-one;
3-(4-Methoxy-phenyl)-7-methyl-1-(2-oxo-2-piperidin-1-yl-ethyl)-1 H-
quinolin-4-one;
N-Ethyl-N-(2-hydroxy-ethyl)-2-[3-(4-methoxy-phenyl)-7-methyl-4-oxo-
4H-quinolin-1-yl]-acetamide;
N-(2-Hyd roxy-ethyl )-2-[3-(4-methoxy-ph enyl )-7-methyl -4-oxo-4 H-
quinolin-1-yl]-N-propyl-acetamide;
N-Cyclopropylmethyl-2-[3-(4-methoxy-phenyl)-7-methyl-4-oxo-4H-
quinolin-1-yl]-N-propyl-acetamide;
N,N-Bis-(2-hydroxy-ethyl)-2-[3-(4-methoxy-phenyl)-7-methyl-4-oxo-4H-
quinolin-l-yl]-acetamide;

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
N,N-Diallyl-2-[3-(4-methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-
acetamide;
N-(3,5-Dimethyl-isoxazol-4-yl)-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-
1-yl)-acetamide;
5 2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-(1-methyl-1 H-pyrazol-3-
yl )-acetam ide;
N-(2,5-Dimethyl-2H-pyrazol-3-yl)-2-(7-methyl-4-oxo-3-phenyl-4H-
quinolin-l-yl)-acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-N-(5-methyl-pyridin-2-yl)-
10 acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-N-[1,3,4]thiadiazol-2-yl-
acetamide;
N-(4-Dimethylam ino-phenyl )-2-(7-methyl-4-oxo-3-phenyl-4 H-q u inol in-1-
yl )-acetam ide;
15 N-(3-Methyl-isoxazol-5-yl)-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-l-yl)-
acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-N-p-tolyl-acetamide;
2-[3-(4-Methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1 -yl]-N-(1-methyl-
1 H-pyrazol-3-yl)-acetamide;
1-[2-(2,5-Dimethyl-2,5-dihydro-pyrrol-1 -yl)-2-oxo-ethyl]-3-(4-methoxy-
phenyl)-7-methyl-1 H-quinolin-4-one;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-N-(5-methyl-2H-pyrazol-3-
yl )-acetam ide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-N-pyridin-2-ylmethyl-
acetamide;
N-(2-Acetyl-thiophen-3-yl)-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-l-yl)-
acetamide;
N-Ethyl-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-N-
[1,3,4]thiadiazol-2-yl-acetamide;
N-(2-Methyl-1 H-indol-5-yl)-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-
acetamide;

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
16
1-[2-(3,6-Dihydro-2H-pyridin-1-yl)-2-oxo-ethyl]-7-methyl-3-phenyl-1 H-
quinolin-4-one;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-(1 H-pyrazol-3-yl)-
acetamide;
N-(4-Fluoro-phenyl)-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-
acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-(5-trifluoromethyl-
[1,3,4]thiadiazol-2-yl)-acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-quinolin-2-yl-acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-N-(2-methyl-2H-pyrazol-3-
yl)-acetamide;
N-(5-Cyclopropyl-2H-pyrazol-3-yl)-2-(7-methyl-4-oxo-3-phenyl-4H-
quinolin-1-yl)-acetamide;
N-Isoquinolin-3-y1-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-
acetamide;
N-Indan-2-y1-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-N-(2-th iophen-2-yl -ethyl)-
acetamide;
7-Bromo-1 -[2-(3,6-dihydro-2H-pyridin-1 -yl)-2-oxo-ethyl]-3-phenyl-1 H-
quinolin-4-one;
(7-Bromo-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetic acid hydrazide;
2-(7-Bromo-4-oxo-3-phenyl-4H-quinolin-1-yl)-N,N-dibutyl-acetamide;
7-Bromo-1 -(2-oxo-2-pyrrolidin-1 -yl-ethyl)-3-phenyl-1 H-quinolin-4-one;
7-Bromo-1 -(2-oxo-2-piperidin-1 -yl-ethyl)-3-phenyl-1 H-quinolin-4-one;
7-Bromo-1-[2-(2,6-dimethyl-morpholin-4-yl)-2-oxo-ethyl]-3-phenyl-1 H-
quinolin-4-one;
N,N-Diallyl-2-(7-bromo-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetamide;
7-Bromo-1 -[2-(2,5-dimethyl-2,5-dihydro-pyrrol-1 -yl)-2-oxo-ethyl]-3-
phenyl-1 H-quinolin-4-one;
2-(7-Bromo-4-oxo-3-phenyl-4H-quinolin-1-yl)-N-cyclopropylmethyl-N-
propyl-acetamide;

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
17
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-N-(5-nitro-thiazol-2-yl)-
acetamide;
N-Isoxazol-3-y1-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-yl)-acetamide;
2-(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-N-(4-methyl-thiazol-2-yl)-
acetamide;
7-Bromo-1 -(2-oxo-2-piperidin-1 -yl-ethyl)-3-phenyl-1 H-quinolin-4-one;
(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-acetic acid methyl ester;
(7-Methyl-4-oxo-3-phenyl-4H-quinolin-1 -yl)-acetic acid;
[3-(4-Methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-acetic acid
methyl ester;
[3-(4-Methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-yl]-acetic acid;
(7-Bromo-4-oxo-3-phenyl-4H-quinolin-1 -yl)-acetic acid;
1-[2-(2,6-Dimethyl-morpholin-4-yl)-2-oxo-ethyl]-3-(4-methoxy-phenyl)-7-
methyl-1 H-quinolin-4-one;
1-[2-(3,5-Dimethyl-piperidin-1-yl)-2-oxo-ethyl]-3-(4-methoxy-phenyl)-7-
methyl-1 H-quinolin-4-one;
N-(6-Methoxy-pyrimidin-4-yl)-2-(7-methyl-4-oxo-3-phenyl-4H-quinolin-1-
yl)-acetamide;
1-[2-(4-Hydroxy-piperidin-1-yl)-2-oxo-ethyl]-7-methyl-3-phenyl-1 H-
quinolin-4-one;
N-Isoxazol-3-yl-2-[3-(4-methoxy-phenyl)-7-methyl-4-oxo-4H-quinolin-1-
yl]-acetamide; and
1-[2-(4-Hydroxy-piperidin-1 -yl)-2-oxo-ethyl]-3-(4-methoxy-phenyl)-7-
methyl-1 H-quinolin-4-one.
Another embodiment of the present invention is to provide a process for
preparing the compounds of formula (I).
The compounds of general structure (I) can be obtained following the
synthetic strategy showed below (Scheme 1):

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
18
Rl 0
R3
I /
0 R2 N Rq
R31,/COOEt + R AOEt y
O(III) (1) R5
(II)
CuBr2 0
NaH / Et20 0 AcOEt I NaH
~ AMe - R5~Br DMF
R5
(XI) (XII)
R, Y
EtOOC R3 EtOOC I~~I R3 Biphenyl Rl 0
R
Y Toluene HN Rq Diphenylether I\ 3
R2 NH2 O/~I Rq \ R N R
I ~ 2 H 4
(IV) (V) Rj / R2 (VII)
(VI) Br-'*'~p1R NaH
9 DMF
0 (VIII)
R, O R, 0
I R3 KOH I R3
EtOH / H2O
R2 N Rq R2 N Rq
OH p
ll R
9
O
( I , R5 = OH) (I, R5 = OR9) O
R6R7NH NH2NHR$ (X)
(IX)
MeOH
WSD/DMAP/DCM
R, O Rl 0
R3 I R3
I I
R2 N R4 R2 N R4
O O
R6 "IN\ R7 H2N' N, Rs
(I, R5 = NR6R7) (I, R5 = N(R8)NH2)
Scheme 1

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
19
Starting from a Claisen condensation between two esters (II) and (III), it is
possible to obtain the 1,3-dicarbonylic system (V), which in reaction with the
aniline (IV) in toluene yields the enamine (VI). The Friedel-Crafts
intramolecular condensation of (VI) at high temperature affords the
quinolone system (VII). This quinolone can be converted into compounds of
general structure (I) by three different ways. The first one is the N-
alkylation
of (VII) by using a substituted 2-bromo ethanone (XII, commercially
available or synthesized from (XI) by bromination). On the other hand, the
latter quinolone (VII) can be N-substituted by using an alkyl bromoacetate
(VIII) to yield (I, R5 = OR9). Methyl and ethyl bromoacetates are preferred.
More preferred is methyl bromoacetate. The ester group present in (I, R5 =
OR9) can be substituted by an hydrazine (X), giving the final hydrazide
compound (I, R5 = N(R8)NH2), Finally, esters (I, R5 = OR9) can be converted
into acids (I, R5 = OH) by conventional saponification, and these acids, by
coupling with amines (IX), yield compounds (I) when the functional group to
obtain is an amide.
The compounds of the present invention or their pharmaceutically
acceptable salts or hydrates can be used for the preparation of a
medicament for treating or preventing diseases associated with GABAA
receptor modulation in a human or non-human mammal. More specifically,
diseases associated with GABAA receptor modulation comprise diseases
associated with a,-GABAA receptor modulation and/or a2-GABAA receptor
modulation. A non-limitative list of such diseases comprises anxiety,
epilepsy, sleep disorders, including insomnia, and the like.
Another embodiment of the present invention is to provide the use of a
compound of the present invention or a pharmaceutically acceptable salt or
hydrate thereof for the preparation of a medicament for treating or
preventing anxiety in a human or non-human mammal.

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
Another embodiment of the present invention is to provide the use of a
compound of the present invention or a pharmaceutically acceptable salt or
hydrate thereof for the preparation of a medicament for treating or
preventing epilepsy in a human or non-human mammal in need thereof.
5
Another embodiment of the present invention is to provide the use of a
compound of the present invention or a pharmaceutically acceptable salt or
hydrate thereof for the preparation of a medicament for treating or
preventing sleep disorders in a human or non-human mammal in need
10 thereof.
Another embodiment of the present invention is to provide the use of a
compound of the present invention or a pharmaceutically acceptable salt or
hydrate thereof for the preparation of a medicament for treating or
15 preventing insomnia in a human or non-human mammal in need thereof.
Another embodiment of the present invention is to provide the use of a
compound of the present invention or a pharmaceutically acceptable salt or
hydrate thereof for the preparation of a medicament for inducing sedation-
20 hypnosis in a human or non-human mammal in need thereof.
Another embodiment of the present invention is to provide the use of a
compound of the present invention or a pharmaceutically acceptable salt or
hydrate thereof for the preparation of a medicament for inducing anesthesia
in a human or non-human mammal in need thereof.
Another embodiment of the present invention is to provide the use of a
compound of the present invention or a pharmaceutically acceptable salt or
hydrate thereof for the preparation of a medicament for modulating the
necessary time to induce sleep and its duration in a human or non-human
mammal in need thereof.

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
21
Another embodiment of the present invention is to provide the use of a
compound of the present invention or a pharmaceutically acceptable salt or
hydrate thereof for the preparation of a medicament for inducing muscle
relaxation in a human or non-human mammal in need thereof.
The present invention also relates to a method of treatment or prevention of
a human or non-human mammal suffering from diseases associated with
GABAA receptor modulation in a human or non-human mammal, which
comprises administering to said human or non-human mammal in need
thereof a therapeutically effective amount of a compound of the present
invention or pharmaceutically acceptable salts or hydrates thereof, together
with pharmaceutically acceptable diluents or carriers. More specifically,
diseases associated with GABAA receptor modulation comprise diseases
associated with a,-GABAA receptor modulation and/or a2-GABAA receptor
modulation. A non-limitative list of such diseases comprises anxiety,
epilepsy, sleep disorders, including insomnia, and the like.
Further preferred embodiments of the invention relate to:
a method for treating or preventing diseases associated with the GABAA
receptor modulation in a human or non-human mamal in need thereof,
which comprises administering to said mammal an effective amount of a
compound of formula I as defined above, wherein, preferably, the GABAA
receptor is the a,-GABAA receptor and/or a a2-GABAA receptor;
a method for treating or preventing anxiety in a human or non-human
mammal in need thereof, which comprises administering to said mammal
an effective amount of a compound of formula I as defined above;
a method for treating or preventing epilepsy in a human or non-human
mammal in need thereof, which comprises administering to said mammal
an effective amount of a compound of formula I as defined above;

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
22
a method for treating or preventing sleep disorders in a human or non-
human mammal in need thereof, which comprises administering to said
mammal an effective amount of a compound of formula I as defined above;
a method for treating or preventing insomnia in a human or non-human
mammal in need thereof, which comprises administering to said mammal
an effective amount of a compound of formula I as defined above;
a method for inducing sedation hypnosis in a human or non-human
mammal in need thereof, which comprises administering to said mammal
an effective amount of a compound of formula I as defined above;
a method for inducing anesthesia in a human or non-human mammal in
need thereof, which comprises administering to said mammal an effective
amount of a compound of formula I as defined above;
a method for for modulating the necessary time to induce sleep and its
duration in a human or non-human mammal in need thereof, which
comprises administering to said mammal an effective amount of a
compound of formula I as defined above; and
a method for inducing muscle relaxation in a human or non-human mammal
in need thereof, which comprises administering to said mammal an
effective amount of a compound of formula I as defined above.
As used herein, the term "mammal" shall refer to the Mammalian class of
higher vertebrates. The term "mammal" includes, but is not limited to, a
human.
Another embodiment of the present invention is to provide a pharmaceutical
composition containing a compound of the present invention or

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
23
pharmaceutically acceptable salts and hydrates thereof, in association with
therapeutically inert carriers.
The compositions include those suitable for oral, rectal and parenteral
(including subcutaneous, intramuscular, and intravenous) administration,
although the most suitable route will depend on the nature and severity of
the condition being treated. The most preferred route of the present
invention is the oral route. The compositions may be conveniently
presented in unit dosage form, and prepared by any of the methods well
known in the art of pharmacy.
The active compound can be combined with a pharmaceutical carrier
according to conventional pharmaceutical compounding techniques. The
carrier may take a wide variety of forms depending on the form of the
preparation desired for administration, e.g. oral or parenteral (including
intravenous injections or infusions). In preparing the compositions for oral
dosage form any of the usual pharmaceutical media may be employed.
Usual pharmaceutical media include, for example, water, glycols, oils,
alcohols, flavoring agents, preservatives, coloring agents, and the like, in
the case of oral liquid preparations (such as for example, suspensions,
solutions, emulsions and elixirs); aerosols; or carriers such as starches,
sugars, microcrystalline cellulose, diluents, granulating agents, lubricants,
binders, disintegrating agents and the like, in the case of oral solid
preparations (such as for example, powders, capsules, and tablets) with the
oral solid preparations being preferred over the oral liquid preparations.
Because of their ease of administration, tablets and capsules represent the
most advantageous oral dosage unit form, in which case solid
pharmaceutical carriers are employed. If desired, tablets may be coated by
standard aqueous or non-aqueous techniques.

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
24
A suitable dosage range for use is from about 0.01 mg to about 100.00 mg
total daily dose, given as a once daily administration or in divided doses if
required.
In accordance with the results obtained, certain compounds of the present
invention have evidenced pharmacological activity both in vitro and in vivo,
which has been similar to or higher than that of prior-art compound
zolpidem. All these results support!their use in diseases or conditions
modulated by al- and a2-GABAA receptors, such as insomnia or
anesthesia, in which an induction of sleep, an induction of sedation or an
induction of muscle relaxation are needed.
Thus, surprisingly, some compounds of the present invention have shown
similar or higher affinity for al-subunit of GABAA receptor, which is involved
in the sedative activity. Moreover, this higher affinity correlates well with
the
in vivo activity in a predictive model of sedative-hypnotic activity,
particularly
for compounds of examples 1, 11, 14, 39, 44 and 129 (Table 3 below).
Furthermore, some compounds, in particularly compounds of examples 15,
18 and 32 of the present invention, have displayed higher al- l a2-
selectivity than the most selective therapeutically used compound zolpidem.
In addition, some compounds of the present invention have exhibited a
higher affinity than prior art compound zolpidem for the (X2-subunit of
GABAA receptor, which is involved in anxiety. Compounds of examples 27
and 43 are particularly effective in anxiety related syndromes.
The pharmacological activity of the compounds of the present invention has
been determined as described below.
a) Ligand-binding assays. Determination of the affinity of test compounds
for ai- and ag-GABAe receptor

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
Male Sprague-Dawley rats weighing 200-250 g at the time of experiment
were used. After decapitation of the animal, the cerebellum (tissue that
mostly contains (xi-GABAA receptor) and spinal cord (tissue that mostly
5 contains (X2-GABAA receptor) were removed. The membranes were
prepared according to the method by J. Lameh et al. (Prog. Neuro-
Psychopharmacol. Biol. Psychiatry, 24, 979-991, 2000) and H. Noguchi et
al. (Eur J Pharm, 434, 21-28, 2002) with slight modifications. Once the
tissues weighed, they were suspended in 50 mM Tris.HCl (pH 7.4), 1:40
10 (v/v), or sucrose 0.32 M in the case of spinal cord, homogenized and then
centrifuged at 20,000 g for 10 min at 7 C. The resulting pellet was
resuspended under the same conditions and centrifuged again. The pellet
was finally resuspended on a minimum volume and kept at -80 C
overnight. On the next day, the process was repeated until the final pellet
15 was resuspended at a ratio of 1:10 (v/v) in the case of cerebellum and at a
ratio of 1:5 (v/v) in the case of spinal cord.
Affinity was determined by competitive tests using radiolabeled flumazenil
as ligand. The tests were performed according to the methods described by
20 S. Arbilla et al. (Eur. J. Pharmacol., 130, 257-263, 1986); and Y. Wu et
al.
(Eur. J. Pharmacol., 278, 125-132, 1995) using 96-well microtiter plates.
The membranes containing the study receptors, flumazenil (radiolabeling at
a final concentration of 1 nM) and ascending concentrations of test
compounds (in a total volume of 230 L in 50 mM [pH 7.4] Tris.HCl buffer)
25 were incubated. Simultaneously, the membranes were only incubated with
the radiolabeled flumazenil (total binding, 100%) and in the presence of an
elevated concentration of unradiolabeled flumazenil (non-specific binding,
% estimation of radiolabeled ligand). The reactions started on adding the
radiolabeled ligand followed by incubation for 60 minutes at 4 C. At the end
of the incubation period, 200 L of reaction were transferred to a
multiscreen plate (Millipore) and filtered using a vacuum manifold and then
washed three times with cold test buffer. The multiscreen plates were

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
26
equipped with a GF/B filter that retained the membranes containing the
receptors and the radiolabeled ligand which had been bound to the
receptors. After washing, the plates were left till dry. Once dried,
scintillation
liquid was added and left under stirring overnight. The next day the plates
were counted using a Perkin-Elmer Microbeta scintillation counter.
For analysis of the results the percentage of specific binding for every
concentration of test compound was calculated as follows:
% specific binding =(X-N/T-N) x 100
where,
X: amount of bound ligand for every concentration of compound.
T: total binding, maximum amount bound to the radiolabeled ligand.
N: non-specific binding, amount of radiolabeled ligand bound in a non-
specific way irrespective of the receptor used.
Every concentrations of compound were tested in triplicate and their mean
values were used to determine the experimental values of % specific
binding versus the concentration of compound. Affinity data are expressed
as % inhibition at 10-5M and 10-7M concentrations. The results of these
tests are given in Tables 1 and 2.
Table 1. Affinity for the al-subunit of the GABAA receptor
Rl O
R3
I / I
R2 N R4 % inhibition
YO
R5
(I)
Example R, R2 R3 R4 R5 10"5M 10"7M
1 Me H H Ph N-Morpholinyl 99.5 57.9

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
27
Rl O
R3
I / I
R2 N R4 % inhibition
YO
R5
(I)
Example R, R2 R3 R4 R5 10"5M 10"7M
11 Me H H Ph N-P rrolidin I 99.9 52.6
14 H Me Ph H N(n-Pr)2 98.4 36.7
15 H Me Ph H N-Piperidinyl 87.3 0.0
17 H Me Ph H NEt2 91.4 0.7
18 H Me Ph H N-Pyrrolidinyl 86.2 7.5
27 H Me Ph H 2-Thienyl 97.7 14.0
28 H Me Ph H 2-Pyridyl 97.9 22.5
32 H Me Ph H 2,6-Dimethyl-N-Morpholinyl 86.2 18.4
33 H Me Ph H 2,4-Dimethyl-5-Oxazolyl 97.0 33.9
36 H Me 4-MeOPh H N(n-Pr)2 95.9 20.3
39 H Me Ph H N C cloprop Imeth I Pr 98.8 56.3
42 H Me Ph H 2,5-Dimethyl-3-Pyrrolinyl 97.0 25.6
43 H Me Ph H N(AIIyI)2 99.0 49.9
44 H Br Ph H N(n-Pr)2 99.8 61.9
47 H H Ph H N(n-Pr)2 88.1 2.3
80 H Me 4-MeOPh H NH 4-MeOPh 78.5 28.5
97 H Me 4-MeOPh H N(AIIyI)2 90.7 4.9
129 H Br Ph H N(AIIyI)2 99.7 85.2
zolpidem 99.8 51.9
Table 2. Affinity for the a2-subunit of the GABAA receptor
Rl O
R3
I / I
R2 N R4 % inhibition
YO
R5
(I)
Example R, R2 R3 R4 R5 10"5M 10"7M
14 H Me Ph H N(n-Pr)2 77.3 40.6
15 H Me Ph H N-Piperidinyl 13.3 0.0

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
28
Rl O
R3
I / I
R2 N R4 % inhibition
YO
R5
(I)
Example R, R2 R3 R4 R5 10"5M 10"7M
17 H Me Ph H NEt2 70.1 0.0
18 H Me Ph H N-Pyrrolidinyl 66.3 0.0
27 H Me Ph H 2-Thienyl 89.9 8.4
28 H Me Ph H 2-Pyridyl 88.0 0.0
32 H Me Ph H 2,6-Dimethyl-N-Morpholinyl 55.4 0.0
39 H Me Ph H N C cloprop Imeth I Pr 93.4 28.5
42 H Me Ph H 2,5-Dimethyl-3-Pyrrolinyl 74.1 0.0
43 H Me Ph H N(Allyl)2 88.2 12.5
47 H H Ph H N(n-Pr)2 68.9 0.0
80 H Me 4-MeOPh H NH(4-MeOPh) 65.1 15.7
97 H Me 4-MeOPh H N AII I 2 62.0 0.0
zolpidem 74.1 19.9
b) In vivo determination of predictive sedative-hypnotic action
The in vivo effects of these compounds were assessed by a predictive
sedation-hypnosis test in mice (D. J. Sanger et al., Eur. J. Pharmacol., 313,
35-42, 1996; and G. Griebel et al., Psychopharmacology, 146, 205-213,
1999).
Groups of 5-8 male CD1 mice, weighing 22-26 g at the time of test, were
used. The test compounds were administered in single equimolecular
intraperitoneal doses, suspended in 0.25% agar with one drop of Tween in
a volume of 10 mL/kg. Control animals received the vehicle alone. Using a
Smart System (Panlab, S.L., Spain) the traveled distance in cm was
recorded for each mouse at 5 min intervals during a period of 30 minutes
after dosing. The inhibition percentage traveled distance of treated animals

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
29
versus control animals (the first 5 min were discarded) was calculated. The
results of this test are given in Table 3.
Table 3. Determination of in vivo sedative-hypnotic activity in mice.
Rl O
R3
I / I
R2 N R4
O
R5
(I)
Example R, R2 R3 R4 R5 %(*)
14 H Me Ph H N n-Pr 2 96.22
15 H Me Ph H N-Piperidinyl 84.65
17 H Me Ph H NEt2 81.47
18 H Me Ph H N-Pyrrolidinyl 84.55
27 H Me Ph H 2-Thienyl 70.0
28 H Me Ph H 2-P rid I 84.41
32 H Me Ph H 2,6-Dimethyl-N-Morpholinyl 89.96
33 H Me Ph H 2,4-Dimethyl-5-Oxazolyl 91.67
36 H Me 4-MeOPh H N(n-Pr)2 92.06
39 H Me Ph H N(Cyclopropylmethyl)(Pr) 92.46
42 H Me Ph H 2,5-Dimeth I-3-P rrolin I 92.19
43 H Me Ph H N(Allyl)2 90.99
44 H Br Ph H N(n-Pr)2 95.25
47 H H Ph H N(n-Pr)2 74.72
80 H Me 4-MeOPh H NH 4-MeOPh 71.91
97 H Me 4-MeOPh H N(Allyl)2 76.76
129 H Br Ph H N(Allyl)2 93.52
zolpidem 91.70
(*) % of inhibition spontaneous motor activity (98 pmol/kg)
Preparative examples
Step 1: General method for the Claisen condensation

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
0 A EtOOC R3
NaH / Et20
R3~/COOEt + R4 OEt ~
(III) 0 R4
(II)
(V)
To a solution of acetate (II) (leq) and ester (III) (leq) in ethyl ether 95%
sodium hydride (4eq) was slowly added over a 2 h interval under nitrogen
5 atmosphere. After addition was complete the solution was stirred for 2.5 h.
The mixture was treated with 4.5% HCI and the organic phase was
extracted with diethyl ether and dried (MgSO4). Evaporation of the solvent
gave the title compound (V) in the enolic form, which was used for the next
step without further purification.
Example given for RI=H, R2=Me, R3=Ph, R4=H
1H NMR (CDC13) b 12.13 (d, J=12.6 Hz, 1H, OH), 7.31-7.25 (m, 6 H, 5 Har
+ C=CH), 4.29 (q, J=7.2 Hz, 2 H, CH2-O), 1.29 (t, J=7.2 Hz, 3 H, CH3).
Step 2: General method for the formation of the enamine
EtOOC R3
R1 I
EtOOC R3
Toluene HN R4
R2 NH2 O R4 I
(IV) (V) R R
1 2
(VI)
A solution of ketoester (V) (1.1 eq) and aniline (IV) (leq) in toluene was
refluxed under stirring for 19 hours in a Dean-Stark apparatus. After cooling
toluene (18 mL) was added and the mixture was treated with 10% HCI and
water. The organic phase was dried with MgS04 and the residue obtained
after evaporation was purified by silica gel column chromatography
(hexane/ethyl acetate), to give the title compound (VI).

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
31
Example given for RI=H, R2=Me, R3=Ph, R4=H
'H NMR (CDC13) b 10.30 (d, J=12.6 Hz, 1H, NH), 7.43-6.83 (m, 10 H, 9 Har
+ C=CH), 4.26 (q, J=7.2 Hz, 2 H, CH2-O), 2.33 (s, 3H, CH3-Ph), 1.30 (t,
J=7.2 Hz, 3 H, CH3).
Step 3: General method for the Friedel-Crafts cyclisation
EtOOC R3
I
Biphenyl Rl O
HN R4 Diphenylether R3
-~ I \ I
I \ A R2 H R4
/
Rl R2 (VII)
(VI)
To a solution of biphenyl and diphenyl ether (1:7 molar ratio) heated at 280
C , enamine (VI) was slowly added and the reaction mixture was stirred at
280 C for 20 min. The mixture was cooled with an ice bath and the
precipitate was filtered and washed with hexane to give a mixture of the two
possible isomers. These were separated by column chromatography
(hexane/ethyl acetate) to give the desired product (VII).
Example given for RI=H, R2=Me, R3=Ph, R4=H
'H NMR (DMSO-d6) b 11.9 (br, 1 H, NH), 8.09-7.14 (m, 8 H, Har), 2.44 (s, 3
H, CH3).
Step 4: General method for the N-alkylation (by using (VIII) or (XII))

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
32
Rl O Br/~/R9 R, 0
R3 IOI (VIII) R3
I NaH I
R2)( H R4 DMF R2)( R4
(VII) y~R9
(I, R5 = 0R9 ) O
To a suspension of quinolone (VII) (leq) in dry dimethylformamide (DMF)
under nitrogen atmosphere, 95% sodium hydride (1.6eq) was slowly added.
After addition was complete, a solution of methyl bromoacetate (VIII, R9 =
Me) (2eq) in dry DMF was added and the mixture was heated to 95 C for
3.5 hours. After cooling, the mixture was treated with brine and extracted
with ethyl acetate. The organic phase was dried (MgSO4) and the solvent
was evaporated. The residue obtained was purified by silica gel column
chromatography (hexane/ethyl acetate) to give the title compound (I, R5 =
OMe).
Example given for RI=H, R2=Me, R3=Ph, R4=H
'H NMR (CDC13) b 8.38 (d, J=8.1 Hz, 1H, Har), 7.63-7.60 (m, 2 H, Har),
7.47 (s, 1 H, CH=C), 7.36-7.12 (m, 5 H, Har), 6.75 (s, 1 H, Har), 4.77 (s,
2H, CH2-C=O), 4.10 (s, 3H, OMe), 2.41 (s, 3 H, CH3-Ph).
To substitute the ester group by a hydrazine residue, to a solution of leq of
quinolone-ester in methanol a solution of 5eq of the corresponding
hydrazine (X) in methanol was added and the mixture was heated at reflux
for 24h. The reaction was allowed to cool and the solvent was removed.
Then, acetone was added to the mixture and the solid obtained was filtered
off, washed with acetone and dried, to give the title compound (I,
R5=N(R8)NH2) with an average yield of 90%.
Step 5: General method to proceed with the saponification

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
33
R, O Rl O
R3 R3
I\ I KOH I\ I
R2 N R4 EtOH / H2O R2 N R4
01-1 YOH
R9
(I, R5 = OR9) O (I, R5 = OH)
To a solution of quinolone-ester (I, R5 = OR9) (leq) in ethanol an aqueous
solution of KOH (3eq) was added. The mixture was heated at reflux for 6h.
After cooling, a solution of HCI 6N was added until pH=1. The solid thus
obtained was filtered off, washed with cold water and dried, to give the title
compound (I, R5 = OH).
Step 6: General method for amide formation
R, 0 R, 0
I I R3 R6R7NH (IX) R3
I I
R N R4 WSD/DMAP/DCM R2 N R4
4
OH Ifo
N" (I, R5 = OH) R6 R7
(I, R5 = NR6R7)
To a solution of leq of the quinolone-acid in dichloromethane (DCM) a
solution of 1.5eq of water-soluble carbodiimide (WSC) in DCM was added.
The mixture was stirred for 30 min at room temperature. Then, a solution of
1.5eq of the corresponding amine and 0.5eq of 4-(N,N-dimethylamino)-

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
34
pyridine (DMAP) in DCM was added and the resulting mixture was stirred
for 24h at room temperature. The crude was extracted with HCI 1 N, and the
organic layer was dried and the solvent was removed. The residue was
purified by LCMS. The average yield of the process was 60%.
Example given for RI=H, R2=Me, R3=Ph, R4=H, R6=R7=propyl
'H NMR (CDC13) b 8.38 (d, J=8.1 Hz, 1H, Har), 7.63-7.60 (m, 2 H, Har),
7.47 (s, 1 H, CH=C), 7.36-7.12 (m, 4 H, Har), 6.75 (s, 1 H, Har), 4.77 (s,
2H, CH2-C=O), 3.34-3.29 (m, 4 H, 2 CH2-N), 2.41 (s, 3 H, CH3-Ph), 1.78-
1.51 (m, 4 H, 2 CH2-CH3), 1.03 (t, J=7.2 Hz, 3 H, CH3), 0.87 (t, J=7.2 Hz, 3
H, CH3);
13C NMR b 175.7 (0=0), 164.9 (N-C=0), 142.6, 142.4, 139.8, 135.3, 128.5,
128.0, 127.3, 126.7, 125.1, 125.0, 121.7, 114.4 (Car + 2 C=C), 53.7 (CH2-
C=0), 48.9, 48.1 (2 CH2-N), 22.3, 22.2 (2 CH2-CH3), 20.8 (CH3-Ph), 11.4,
11.4 (2 CH3).

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
Compounds 1-146, Table 4, were prepared according to the above reported
preparative examples.
Table 4
Rl O
R3
I / I
R2 N R4
O
R5
(I)
Number R, R2 R3 R4 R5 Purity LCMS
(%) (M+1)
1 Me H H Ph N-Morpholinyl 98 363.4
2 H Me H Ph NEt2 95 349.4
3 H Me H Ph N-Morpholinyl 97 363.4
4 H Me H Ph OEt 97 322.4
5 H Me H Ph N n-Bu 2 97 405.6
6 Me H H Ph N(iPr)2 99 377.5
7 Me H H Ph N-Pyrrolidinyl 97 347.4
8 H Me H Ph N(n-Pr)2 96 377.5
9 Me H H Ph N n-Hex 2 98 461.7
10 Me H H Ph N-Piperidinyl 97 361.5
11 Me H H Ph N-Pyrrolidinyl 98 347.4
12 H Me H Ph N-Pyrrolidinyl 96 347.4
13 H Me Ph H N(n-Bu)2 95 405.6
14 H Me Ph H N n-Pr 2 99 377.5
15 H Me Ph H N-Piperidinyl 99 361.5
16 H Me Ph H N(n-Hex)2 98 461.7
17 H Me Ph H NEt2 97 349.4
18 H Me Ph H N-Pyrrolidinyl 96 347.4
19 H Me Ph H N-Morpholinyl 100 363.4
20 H Me Ph H N(iPr)2 97 377.5
21 Me H Ph H N(n-Hex)2 98 461.7
22 Me H Ph H N-Piperidinyl 97 361.5
23 Me H Ph H N-Morpholinyl 98 363.4
24 Me H Ph H NEt2 97 349.4
25 Me H Ph H N(n-Bu)2 96 405.6
26 H Me Ph H 3-Pyridyl 100 355.4
27 H Me Ph H 2-Thienyl 98 360.4
28 H Me Ph H 2-P rid I 100 355.4
29 H Me Ph H 4-Pyridyl 97 355.4
30 H Me Ph H N'-Acetyl-N-Piperazinyl 99 404.5
31 H Me Ph H 5-Methyl-2-Furyl 97 358.4

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
36
Rl O
R3
I / I
R2 N R4
O
R5
(I)
Number R, R2 R3 R4 R5 Purity LCMS
(%) (M+1)
32 H Me Ph H 2,6-Dimethyl-N-Morpholinyl 97 391.5
33 H Me Ph H 2,4-Dimethyl-5-Oxazolyl 95 373.4
34 H Me Ph H 2-Pyrazinyl 99 356.4
35 H Me Ph H N'-Methyl-N-Piperazinyl 96 376.5
36 H Me 4-MeOPh H N n-Pr 2 97 407.5
37 H Me 4-CIPh H N(n-Pr)2 97 411.9
38 H Me p-Tolyl H N(n-Pr)2 96 391.5
39 H Me Ph H N(Cyclopropylmethyl)(n-Pr) 99 389.5
40 H Me Ph H 3,5-Dimeth I-N-Piperidin I 98 389.5
41 H Me Ph H 1,2,3,6-Tetrahydropyridin-1-yl 98 359.4
42 H Me Ph H 2,5-Dimethyl-3-Pyrrolin-1-yl 97 373.5
43 H Me Ph H N(AIIyI)2 96 373.5
44 H Br Ph H N(n-Pr)2 95 442.4
45 Br H Ph H N n-Pr 2 96 442.4
46 H Ph Ph H N(n-Pr)2 97 439.6
47 H H Ph H N(n-Pr)2 95 363.5
48 Ph H Ph H N(n-Pr)2 97 439.6
49 H Me p-Tolyl H OMe 100 322.4
50 H Me p-Tolyl H OH 97 308.3
51 H Me 4-CIPh H OMe 98 342.8
52 H Me 4-FPh H OMe 97 326.3
53 H Me 4-FPh H OH 99 312.3
54 H Me 4-CIPh H NHPh 97 403.9
55 H Me 4-CIPh H NH(2-Pyrazinyl) 100 405.9
56 H Me 4-CIPh H OH 99 328.8
57 H Me 4-CIPh H NHNH2 96 342.8
58 H Me p-Tolyl H NHPh 99 383.5
59 H Me 4-FPh H NHPh 98 387.4
60 H Me p-Tolyl H NH(2-Thiazolyl) 99 390.5
61 H Me p-Tolyl H NH(5-Methyl-Isoxazol-3-yl) 96 388.4
62 H Me 4-FPh H NHNH2 96 326.3
63 H Me p-Tolyl H N H N H2 98 322.4
64 H Me 4-CIPh H NH 5-Meth I-Isoxazol-3- I 96 408.9
65 H Me 4-FPh H NH(5-Methyl-Isoxazol-3-yl) 96 392.4
66 H Me Ph H N(Hydroxyethyl)(Et) 100 365.4
67 H Me Ph H N(Hydroxyethyl)(n-Pr) 98 379.5
68 Me H Ph H N(AIIyI)2 100 373.5

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
37
Rl O
R3
I / I
R2 N R4
O
R5
(I)
Number R, R2 R3 R4 R5 Purity LCMS
(%) (M+1)
69 Me H Ph H N(Hydroxyethyl)(n-Pr) 98 379.5
70 H Me Ph H OH 97 294.3
71 Me H Ph H OH 96 294.3
72 H Me 4-CIPh H N(Me)NH2 97 356.8
73 H Me p-Tolyl H N Me NH2 97 336.4
74 H Me 4-FPh H N(Me)NH2 97 340.4
75 H Me 4-FPh H NH(2-Thiazolyl) 97 394.4
76 H Me 4-CIPh H NH(2-Thiazolyl) 98 410.9
77 H Me 4-MeOPh H NH 4-CF3Ph 98 467.5
78 H Me Ph H NH(4-CF3Ph) 96 437.4
79 H Me Ph H NH(4-MeOPh) 97 399.5
80 H Me 4-MeOPh H NH(4-MeOPh) 96 429.5
81 H Me 4-MeOPh H NH(5-Methyl-3-Pyrazolyl) 96 403.5
82 H Me Ph H NH 2-Thiazol I 96 376.4
83 H Me 4-MeOPh H NH(2-Thiazolyl) 97 406.5
84 H Me Ph H NH(3-Methyl-2-Thienylmethyl) 97 403.5
85 H Me 4-MeOPh H NH(3-Methyl-5-Isoxazolyl) 96 404.4
86 H Me 4-MeOPh H NH(3-Methyl-6-Pyridyl) 98 414.5
87 H Me Ph H NH 2-P rimid I 97 371.4
88 H Me Ph H NH(2-Furylmethyl) 97 373.4
89 H Me 4-MeOPh H NH(1,3-Dimethyl-5-Pyrazolyl) 99 417.5
90 H Me 4-MeOPh H NEt2 99 379.5
91 H Me 4-MeOPh H N-P rrolidin I 96 377.5
92 H Me 4-MeOPh H N-Piperidinyl 98 391.5
93 H Me 4-MeOPh H N(Hydroxyethyl)(Et) 96 395.5
94 H Me 4-MeOPh H N(Hydroxyethyl)(n-Pr) 96 409.5
95 H Me 4-MeOPh H N(Cyclopropylmethyl)(n-Pr) 99 419.5
96 H Me 4-MeOPh H N H drox eth I 2 96 411.5
97 H Me 4-MeOPh H N(AIIyI)2 98 403.5
98 H Me Ph H NH(3,5-Isoxazol-4-yl) 99 388.4
99 H Me Ph H NH(1-Methyl-3-Pyrazolyl) 100 373.4
100 H Me Ph H NH(2,5-Dimethyl-3-Pyrazolyl) 95 387.5
101 H Me Ph H NH 5-Meth I-2-P ridin I 95 384.5
102 H Me Ph H NH(1,3,4-Thiadiazol-2-yl) 98 377.4
103 H Me Ph H NH(4-Dimethylamino-Ph) 95 412.5
104 H Me Ph H NH(3-Methylisoxazol-5-yl) 98 374.4
105 H Me Ph H NH(p-Tolyl) 96 383.5

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
38
Rl O
R3
I / I
R2 N R4
O
R5
(I)
Number R, R2 R3 R4 R5 Purity LCMS
(%) (M+1)
106 H Me 4-MeOPh H NH(1-Methyl-3-Pyrazolyl) 99 403.5
107 H Me 4-MeOPh H NH(2,5-Dimethyl-3-Pyrrolinyl) 96 403.5
108 H Me Ph H NH(5-Methyl-3-Pyrazolyl) 95 373.4
109 H Me Ph H NH(2-Pyridylmethyl) 98 384.5
110 H Me Ph H NH 2-Acet I-3-Thien I 95 417.5
111 H Me Ph H N(Et)(1,3,4-Thiadiazol-2-yl) 99 405.5
112 H Me Ph H NH(2-Methyl-5-Indolyl) 98 422.5
113 H Me Ph H NH(1,2,3,6-Tetrahydro-N-pyridyl) 96 359.4
114 H Me Ph H NH 3-P razol I 98 359.4
115 H Me Ph H NH(4-FPh) 97 387.4
116 H Me Ph H NH[5-(CF3)-1,3,4-Thiadiazol-2-yl] 98 445.4
117 H Me Ph H NH(2-Quinolyl) 99 420.5
118 H Me Ph H NH(2-Methyl-3-Pyrazolyl) 98 373.4
119 H Me Ph H NH 5-C cloprop I-3-P razol I 98 399.5
120 H Me Ph H NH(2-Quinolyl) 97 420.5
121 H Me Ph H NH(2-Indanyl) 96 409.5
122 H Me Ph H NH(2-Thienylethyl) 99 403.5
123 H Br Ph H 1,2,3,6-Tetrahydropyridyl 97 424.3
124 H Br Ph H NHNH2 98 373.2
125 H Br Ph H N(n-Bu)2 97 470.4
126 H Br Ph H N-Pyrrolidinyl 99 412.3
127 H Br Ph H N-Piperidinyl 96 426.3
128 H Br Ph H 2,6-Dimeth I-N-Morpholin I 97 456.4
129 H Br Ph H N(AIIyI)2 99 438.3
130 H Br Ph H 2,5-Dimethyl-3-Pyrrolinyl 97 438.3
131 H Br Ph H N(Cyclopropylmethyl)(n-Pr) 96 454.4
132 H Me Ph H NH(5-Nitro-2-Thiazol-2-yl) 99 421.4
133 H Me Ph H NH 3-Oxazol I 98 360.4
134 H Me Ph H NH(4-Methyl-2-Thiazolyl) 99 390.5
135 H Br Ph H N-Piperidinyl 96 426.3
136 H Me Ph H OMe 97 308.3
137 H Me Ph H OH 98 294.3
138 H Me 4-MeOPh H OMe 96 338.4
139 H Me 4-MeOPh H OH 98 324.3
140 H Br Ph H OH 99 359.2
141 H Me 4-MeOPh H 2,6-Dimethyl-N-Morpholinyl 97 421.5
142 H Me 4-MeOPh H 3,5-Dimethyl-N-Piperidinyl 100 419.5

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
39
Rl O
R3
I / I
R2 N R4
O
R5
(I)
Number R, R2 R3 R4 R5 Purity LCMS
(%) (M+1)
143 H Me Ph H NH(6-Methoxy-4-Pyrimidinyl) 96 401.4
144 H Me Ph H 4-Hydroxy-N-Piperidinyl 98 377.5
145 H Me 4-MeOPh H NH(3-Isoxazolyl) 96 390.4
146 H Me 4-MeOPh H 4-Hydroxy-N-Piperidinyl 99 407.5
Composition example 1: 5 mg tablets
Active ingredient 5.0 mg
Colloidal silicon dioxide 0.6 mg
Croscarmellose sodium 12.0 mg
Talc 4.0 mg
Magnesium stearate 1.5 mg
Polysorbate 80 1.0 mg
Lactose 75.0 mg
Hydroxypropyl methylcellulose 3.0 mg
Polyethylene glycol 4000 0.5 mg
Titanium dioxide E171 1.5 mg
Microcrystalline cellulose q.s. to 125.0 mg
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . ,
Composition example 2: 10 mg capsules
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . ,
Active ingredient 10.0 mg
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Colloidal silicon dioxide 0.6 mg
Crospovidone 12.0 mg
Talc 4.0 mg

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
Magnesium stearate 1.5 mg
Lauryl sulfate sodium 1.5 mg
Lactose 77.0 mg
Gelatin 28.5 mg
Titanium dioxide E171 1.5 mg
Indigotin E132 0.02 mg
Microcrystalline cellulose q.s. to 155.0 mg
Composition example 3: oral drops
Active ingredient 0.5 g
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - ~
Propylene glycol 10.0 g
Glycerin 5.0 g
Saccharin sodium 0.1 g
Polysorbate 80 1.0 g
Lemon flavor 0.2 g
Ethanol 25.0 mL
Purified water q.s. to 100.0 mL
5 Composition example 4: 2.5 mg tablets
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . ,
Active ingredient 2.5 mg
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Colloidal silicon dioxide 0.6 mg
Croscaramellose sodium 12.0 mg
Talc 4.0 mg
Magnesium stearate 1.5 mg
Polysorbate 80 1.0 mg
Lactose 75.0 mg
Hydroxypropyl methylcellulose 3.0 mg
Polyethylene glycol 4000 0.5 mg
Titanium dioxide E171 1.5 mg
Microcrystalline cellulose q.s. to 125.0 mg
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - ~

CA 02660421 2009-02-09
WO 2008/017710 PCT/EP2007/058288
41
Composition example 5: 5 mg capsules
Active ingredient 5.0 mg
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Colloidal silicon dioxide 0.6 mg
Crospovidone 12.0 mg
Talc 4.0 mg
Magnesium stearate 1.5 mg
Lauryl sulfate sodium 1.5 mg
Lactose 77.0 mg
Gelatin 28.5 mg
Titanium dioxide E171 1.5 mg
Indigotin E132 0.02 mg
Microcrystalline q.s.to 155.0 mg
~ - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Composition example 6: Oral drops
~ - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Active ingredient 0.25 g
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Propylene glycol 10.0 g
Glycerin 5.0 g
Saccharin sodium 0.1 g
Polysorbate 80 1.0 g
Lemon flavor 0.2 g
Ethanol 25.0 mL
Purified q.s. to 100.0 mL
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Abbreviations used throughout the specification:
Me = methyl; Et = ethyl; nPr = n-propyl; iPr = I-propyl; n-Bu = n-butyl ; n-
Hex = n-hexyl ; Ph = phenyl

Dessin représentatif